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SUMMARY  
γ-Aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the brain and plays a 
major role in determining the routing or sculpting of neural activity, as well as limiting 
excessive neuronal firing, via the fast-acting ionotropic GABAA receptors and the slow-acting 
metabotropic GABAB receptors. Functional GABAB receptors are heterodimers comprising 
the subunits GABAB1 and GABAB2. Presynaptically, GABAB receptors inhibit voltage-gated 
Ca
2+
 channels and suppress neurotransmitter release whereas postsynaptically they induce 
slow inhibitory postsynaptic potentials by activation of Kir3-type K
+
 channels. Dysfunction of 
GABAB receptors in the CNS is believed to be involved in various nervous system disorders 
such as addiction, anxiety, epilepsy, chronic pain and depression. Elucidation of the 
regulation of GABAB receptor signalling is essential for the understanding of the contribution 
of GABAB receptors to pathophysiological conditions. In this respect, the dynamic control of 
cell surface expression of the receptors is a main factor regulating GABAB receptor 
signalling. The aim of this thesis was to analyze to which extent degradation mechanisms 
regulate cell surface expression of GABAB receptors. 
The research program was divided into three sub-projects. In project one we tested the 
hypothesis that the endoplasmic reticulum (ER)-associated protein degradation (ERAD) 
machinery may contribute to the regulation of GABAB receptor expression levels. We found 
that bidirectional modulation of proteasome activity increased and decreased, respectively, the 
expression level of GABAB receptors in cultured cortical neurons. Proteasomal degradation of 
GABAB receptors required K48-linked ubiquitination of two lysine residues in the C-terminal 
domain of GABAB2. Blocking proteasome activity in neurons resulted in the accumulation of 
GABAB receptors in the endoplasmic reticulum, indicating that the degradation is mediated 
by the proteasome-dependent ERAD machinery. Pharmacological inhibition of ERAD or 
over-expression of a dominant-negative mutant form of VCP/p97, an essential protein of the 
ERAD complex, increased total as well as cell surface levels of GABAB receptors in neurons. 
In conclusion, our results indicate that the level of newly synthetized GABAB receptor in the 
ER available for cell surface trafficking is regulated by ERAD.  
In project two; we searched for GABAB receptor-interacting proteins involved in proteasomal 
degradation and tested the hypothesis that proteasomal degradation might be regulated by 
neuronal activity. We found that the C-terminus of GABAB2 interacts with Rpt6, one of the 
six AAA-ATPases of the 19S regulatory complex of the proteasome. Overexpression of Rpt6 
in HEK293 cells strongly reduced the levels of co-expressed GABAB2, whereas deletion of 
the C terminal domain of GABAB2 or a synthetic peptide comprising the GABAB2 interaction 
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site prevented the Rpt6-mediated down-regulation of GABAB2. Blocking proteasomal activity 
in neurons increased the co-localization of GABAB receptors with Rpt6 and their expression 
level. A non-functional mutant of Rpt6 lacking its ATPase activity prevented degradation of 
GABAB receptors. Blocking ERAD activity decreased the interaction of Rpt6 with GABAB 
receptors, resulting in increased total as well as cell surface expression of the receptors. In 
addition, manipulation of neuronal activity, which had been shown to modulate proteasomal 
activity, affected cell surface expression of GABAB receptors and their interaction with Rpt6. 
In conclusion, these results suggest that the GABAB2/Rpt6 interaction targets GABAB 
receptors to proteasomal degradation via the ERAD machinery in a neuronal activity-
dependent manner and thereby regulates cell surface expression of GABAB receptors. This 
mechanism is expected to play an important role in homeostatic plasticity. 
In the last project, we tested whether lysosomal degradation regulates cell surface expression 
of GABAB receptors and whether ubiquitination is a signal for directing the receptors to 
lysosomes. Inhibition of lysosomal activity in cortical neurons increased total and surface 
GABAB receptors, as well as K63-ubiquitination of the receptors. Mutational inactivation of 
four putative ubiquitination sites in GABAB1 significantly diminished K63-linked 
ubiquitination of GABAB1 and prevented an increase of their expression after 
pharmacological inhibition of lysosomal activity as well as by overexpressing a dominant-
negative mutant of Rab7. This finding suggests that ubiquitination of GABAB1 is a signal for 
lysosomal targeting. Furthermore, we demonstrate that lysosomal degradation of GABAB 
receptors is controlled by Ca
2+
/calmodulin-dependent protein kinase II (CaMKII), which 
modulates K63-ubiquitination of GABAB1. Overexcitation of neurons via prolonged exposure 
to glutamate, a condition that occurs in brain ischemia, rapidly down-regulates GABAB 
receptors through lysosomal degradation. Here we found that glutamate-induced down-
regulation of GABAB receptors critically depends on CaMKII-mediated K63-linked 
ubiquitination of the receptors.  
In conclusion, the present study revealed that proteasomal and lysosomal degradation 
pathways adjust cell surface expression of GABAB receptors according to the activity state of 
the neuron under physiological as well as pathological conditions. 
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ZUSAMMENFASSUNG 
-Aminobuttersäure (GABA) ist der vorherrschende inhibitorische Neurotransmitter im 
Gehirn und ist ursächlich an der Regulation neuronaler Aktivität beteiligt. Die Wirkung von 
GABA wird über die ionotropen GABAA-Rezeptoren und die metabotropen GABAB-
Rezeptoren vermittelt. GABAB-Rezeptoren sind heterodimere Proteinkomplexe, die sich aus 
den Untereinheiten GABAB1 und GABAB2 zusammensetzen. Präsynaptische GABAB-
Rezeptoren inhibieren spannungsabhängige Ca
2+
-Kanäle und verringern dadurch die 
Freisetzung von Neurotransmittern während postsynaptische GABAB-Rezeptoren K
+
-Kanäle 
aktivieren und so langsame, inhibitorische postsynaptische Potentiale induzieren. Es 
existieren Hinweise darauf, dass eine Fehlfunktion von GABAB-Rezeptoren im ZNS an einer 
Vielzahl von neurologischen Erkrankungen beteiligt ist, wie z. B. Angststörungen, 
chronischen Schmerzen, Depressionen, Epilepsie und Sucht. Für ein Verständnis der 
Beteiligung von GABAB-Rezeptoren an neurologischen Erkrankungen ist daher die 
Aufklärung seiner Regulationsmechanismen von wesentlicher Bedeutung. In dieser Hinsicht 
ist die dynamische Kontrolle der Zelloberflächen-Expression der GABAB-Rezeptoren ein 
Hauptfaktor der die Signalstärke dieser Rezeptoren determiniert. Das Anliegen dieser Studie 
war aufzuklären in welchem Ausmass Degradations-Mechanismen die Expression der 
GABAB-Rezeptoren an der Zelloberfläche regulieren. 
Das Forschungsprogramm bestand aus drei Projekten. In Projekt 1 wurde die Hypothese 
getestet ob die „Endoplasmatische Retikulum (ER) assoziierte Protein Degradation“ (ERAD) 
an der Regulation der Zelloberflächen-Expression von GABAB-Rezeptoren beteiligt ist. Die 
Untersuchungen ergaben, dass die Inhibition oder die Stimulierung der Proteasomen-Aktivität 
die GABAB-Rezeptor-Expression in kultivierten Neuronen erhöhte bzw. verringerte. Für die 
proteasomale Degradation der GABAB-Rezeptoren war eine K48-Polyubiquitinierung von 
zwei Lysinen in der C-terminalen Domäne von GABAB2 notwendig. Die Blockierung der 
proteasomalen Aktivität führte zu einer Akkumulierung der GABAB-Rezeptoren im ER. Dies 
deutet darauf hin, dass die Rezeptoren durch die Proteasomen-abhängige ERAD-Maschinerie 
abgebaut werden. Die pharmakologische Inhibition von ERAD oder die Überexpression einer 
funktionell inaktiven Mutante von VCP/p97, einer essenziellen Komponente des ERAD-
Komplexes, erhöhte die totale und Zelloberflächen-Expression der GABAB-Rezeptoren in 
Neuronen. Die Resultate dieser Untersuchungen zeigen, dass die Menge an neu gebildeten 
GABAB-Rezeptoren im ER, welche an die Zelloberfläche exportiert werden können, durch 
ERDA reguliert wird. 
In Projekt 2 wurde nach GABAB-Rezeptor interagierenden Proteinen gesucht, die an der 
proteasomalen Degradation der Rezeptoren beteiligt sind und der Frage nachgegangen ob die 
proteasomale Degradation der Rezeptoren durch die neuronale Aktivität reguliert wird. Die 
Untersuchungen ergaben, dass der C-Terminus von GABAB2 mit Rpt6 interagiert, einer der 
sechs AAA-ATPasen der 19S regulatorischen Untereinheit des Proteasoms. Überexpression 
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von Rpt6 in HEK203 Zellen führte zu einer starken Abnahme der Menge an koexprimiertem 
GABAB2. Die Deletion der C-terminalen Domäne von GABAB2 oder ein synthetisches Peptid, 
welches die GABAB2/Rpt6-Bindungsstelle repräsentiert, verhinderte die Rpt6 vermittelte 
Herunterregulierung von GABAB2. Die Blockierung der proteasomalen Aktivität in Neuronen 
verstärkte die Kolokalisation der GABAB-Rezeptoren mit Rpt6 sowie das Expressionsniveau 
der Rezeptoren. Weiterhin konnte gezeigt werden, dass eine funktionell inaktive Rpt6 
Mutante den Abbau der Rezeptoren verhinderte und die Inhibition von ERAD zu einer 
verminderten GABAB-Rezeptor/Rpt6-Interaktion sowie zu einem erhöhten Expressionsniveau 
totaler und Zelloberflächen-Rezeptoren führte. Die Manipulation der neuronalen Erregung, 
welche wiederum die Aktivität der Proteasomen moduliert, beeinflusste die GABAB-
Rezeptor/Rpt6-Interaktion und als Konsequenz die Zelloberflächen-Expression der 
Rezeptoren. Diese Ergebnisse zeigen, dass die Interaktion von Rpt6 mit GABAB2 essentiell ist 
für den proteasomalen Abbau der GABAB-Rezeptoren durch die ERAD-Maschinerie. Das 
Ausmass des proteasomale Abbaus der Rezeptoren wird durch den Aktivitätszustand des 
Neurons bestimmt und dadurch die Zelloberflächenexpression der GABAB-Rezeptoren 
reguliert. Dieser Mechanismus spielt höchst wahrscheinlich eine wichtige Rolle in der 
homeostatischen Plastizität der Neurone. 
Im letzten Projekt (Projekt 3) wurde der Frage nachgegangen inwieweit die lysosomale 
Degradation der GABAB-Rezeptoren deren Zelloberflächen-Expression reguliert und ob 
Ubiquitiniertung der Rezeptoren als lysosomales Sortierungssignal dient. Inhibition der 
lysosomalen Aktivität in Neuronen erhöhte die Expression sowohl der totalen als auch der 
Zelloberflächen-Rezeptoren sowie deren K63-Ubiquitinierung. Die Inaktivierung von vier 
potenziellen Ubiquitinierungsstellen in GABAB1 durch gerichtete Mutagenese verminderte die 
K63-Ubiquitinierung von GABAB1 beträchtlich und verhinderte die erhöhte GABAB-
Rezeptor-Expression nach Blockierung der lysosomalen Aktivität. Dieses Resultat weist 
darauf hin, dass Ubiquitinierung von GABAB1 ein Signal für den lysosomalen Abbau der 
Rezeptoren ist. Weiterhin ergaben die Untersuchungen, dass die lysosomale Degradation der 
GABAB-Rezeptoren durch die Ca
2+
/Calmodulin-abhängige Proteinkinase II (CaMKII) 
reguliert wird via Modulation der K63-Ubiquitinierung von GABAB1. Übererregung von 
Neuronen durch anhaltende Applikation von Glutamat, eine Situation die bei der zerebralen 
Ischämie auftritt, führt zu einer schnellen Herunterregulierung der GABAB-Rezeptoren durch 
verstärkten lysosomalen Abbau. Unsere Untersuchungen ergaben, dass die Glutamat-
induzierte Herunterregulierung der GABAB-Rezeptoren von der CaMKII-vermittelten K63-
Ubiquitinierung der Rezeptoren abhängt. 
Die Ergebnisse dieser Arbeit ergaben, dass sowohl der proteasomale als auch der lysosomal 
Abbauweg die Zelloberflächen-Expression der GABAB-Rezeptoren in Abhängigkeit von der 
neuronal Aktivität unter physiologischen wie auch unter pathologischen Bedingungen 
reguliert.  
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GABA RECEPTORS  
γ-Aminobutyric acid (GABA) is the most important inhibitory neurotransmitter in the central 
nervous system. GABA mediates its action via the ionotropic GABAA receptors and the 
metabotropic GABAB receptors (Bettler et al 2004a). Upon binding of GABA, GABAA 
receptors mediate fast synaptic inhibition by activation of an intrinsic chloride channel, 
whereas GABAB receptors mediate slow and prolonged neuronal inhibition by indirectly 
affecting downstream effector systems via Gi/o proteins. GABAB receptors are distributed 
throughout the central nervous system and are expressed both in inhibitory and in excitatory 
neurons (Fritschy et al 1999, Fritschy et al 2004). GABAB receptors are involved in the 
regulation of virtually all main brain functions like synaptic plasticity (Pinard et al 2010), 
neuronal network activity (Craig & McBain 2014, Kohl & Paulsen 2010) and neuronal 
development (Gaiarsa et al 2011, Gaiarsa & Porcher 2013). Accordingly, GABAB receptors 
have been implicated in a variety of neurological disorders including anxiety, chronic pain, 
depression, drug addiction, epilepsy and spasticity (Benarroch 2012, Bettler et al 2004a, 
Bowery et al 2004, Bowery 2006, Bowery et al 2002, Cryan & Kaupmann 2005, Kumar et al 
2013, Mombereau et al 2005).  
 
STRUCTURE OF GABAB RECEPTORS 
Functional GABAB receptors are heterodimers comprising the subunits GABAB1 and 
GABAB2. Both subunits are integral membrane proteins containing seven transmembrane 
domains (TM), a large extracellular domain constituting a “Venus fly-trap” domain and a 
large C-terminal domain with a coiled-coil structure that serves as a binding domain for 
several interacting proteins (Fig.1) (Bettler et al 2004a). Assembly of GABAB subunits takes 
place in the endoplasmatic reticulum (ER) is required for leaving the ER and trafficking to the 
plasma membrane. GABAB1 contains an ER retention signal (RSRR) near the coiled-coil 
domain, which prevents ER exit of unassembled GABAB1 (Couve et al 1998, Margeta-
Mitrovic et al 2000, Pagano et al 2001a) by binding to the coat protein complex I (COPI) 
(Brock et al 2005). Assembly with GABAB2 masks the GABAB1 RSRR motif and permits 
forward trafficking of the heterodimeric receptor (Pagano et al 2001a). 
Within the receptor complex, both subunits fullfil distinct functions: GABAB1 harbors the 
binding site for orthosteric ligands in the extracellular “Venus fly-trap” domain, while the 
Venus fly-trap domain present in GABAB2 is constantly in a closed conformation preventing 
ligand binding (Galvez et al 1999, Geng et al 2013). GABAB2 contains a binding site for 
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allosteric modulators within the transmembrane domain (Binet et al 2004) and recruits the Gi/o 
proteins (Duthey et al 2002, Galvez et al 2001, Havlickova et al 2002, Robbins et al 2001) . 
GABAB1 exists in two main variants, GABAB1a and GABAB1b (Fig. 1), which is generated by 
alternative promoter usage (Steiger et al 2004). Accordingly, they constitute the two GABAB 
receptor subtypes (GABAB1a,2 and GABAB1b,2), which are abundantly expressed throughout 
the brain with distinct but overlapping expression patterns in the developing and adult brain 
(Benke et al 1999, Fritschy et al 1999, Fritschy et al 2004, Vigot et al 2006) . GABAB1a and 
GABAB1b solely differ in their N-terminus by the presence of a pair of sushi domains (protein-
protein interaction domains) in GABAB1a, which have been shown to be involved in axonal 
targeting of GABAB1a,2 receptors (Biermann et al 2010)and in increased cell surface stability 
of the receptors (Hannan et al 2012).  
 
EFFECTOR SYSTEMS OF GABAB RECEPTOR 
GABAB receptors recruit and activate Gi/o type G proteins (Campbell et al 1993, Duthey et al 
2002, Galvez et al 2001, Havlickova et al 2002, Robbins et al 2001). Activation of GABAB 
receptors mainly triggers adenylyl cyclase-mediated effects, inhibits ion channel-mediated 
transmitter release and regulates neuronal excitability (Gage 1992, Hill 1985, Hill et al 1984) 
(Fig.1). 
At presynaptic sites, activation of GABAB receptors inhibits neurotransmitter release by 
reducing the activity of P/Q- and N-type voltage-gated Ca
2+
 channels via G (Fox et al 1978, 
Pierau & Zimmermann 1973). In addition, Gi/o of the GABAB receptor-activated G protein 
contributes to the inhibition of transmitter release by increasing the energy barrier for vesicle 
fusion (Rost et al 2011). Under conditions of sustained neuronal activity, GABAB receptor 
activated Gi/o retards recruitment of synaptic vesicles due to decreased cAMP levels (Sakaba 
& Neher 2003).  
At postsynaptic sites, GABAB receptor-activated Gβγ triggers the opening of inwardly 
rectifying K
+
 channels (Kir3 type), thereby inducing slow inhibitory postsynaptic currents 
(Bormann 1988, Dutar & Nicoll 1988, Luscher et al 1997, Wagner & Dekin 1993). GABAB 
receptor-activated Gi/o inhibits adenylate cyclases, resulting in decreased intracellular cAMP 
levels and consequently diminished cAMP-dependent protein kinase (PKA) activity (Karbon 
et al 1984, Watling & Bristow 1986, Wojcik & Neff 1984). This has two main GABAB 
receptor-mediated effects. First, the reduced PKA activity releases a tonic block from two 
pore K
+
 channels (TREK1/2), which induces an inhibitory postsynaptic current (Deng et al 
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2009, Sandoz et al 2012). Second, Ca
2+
 signals mediated by NMDA receptors, which are 
controlled by PKA activity, are inhibited by activation of GABAB receptors (Chalifoux & 
Carter 2010). This is suggested to influence NMDA receptor-dependent synaptic plasticity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Structure and effector systems of GABAB receptors. The GABAB receptor is a 
heterodimer comprising the two subunits GABAB1 and GABAB2. GABAB1 exists in two variants, 
GABAB1a and GABAB1b. They differ only in the N-terminus by the presence of two sushi repeates in 
GABAB1a. The two subunits subserve distinct functions. Whereas GABAB1 is responsible for binding 
of orthosteric ligands, GABAB2 contains a binding site of allsteric modulators and recruits G proteins 
of the Gi/o type. The α subunit of the activated G protein inhibits the adenylate cyclase (AC), which 
leads to diminished cAMP levels and reduced PKA activity. This in turn activates TREK1/2 K
+
 
channels and inhibits Ca
2+
 signals mediated by NMDA receptors. Depending on the localization, the 
βγ dimer of the activated G protein regulates distinct effector system. At postsynaptic sites, Gβγ 
triggers the opening of inwardly rectifying K
+
 channels (Kir 3) resulting in the hyperpolarization of the 
membrane. Presynaptic GABAB receptors repress the opening of Ca
2+
 channels and thereby the 
transmitter. 
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GABAB RECEPTOR TRAFFICKING  
The number of GABAB receptors available for signaling is determined by various 
mechanisms including the amount of receptor synthesis, maturation and assembly of the 
receptors, their kinetic of forward transport from the ER to the plasma membrane, their rates 
of endocytosis from and recycling to the cell surface as well as their rate of degradation. All 
these events control the life time and presence of the receptors at the cell surface and thus 
determine to a large extent their maximal possible signaling strength (Fig. 2). 
To date little is known about the synthesis, folding, assembly and forward trafficking of 
GABAB receptors to the cell surface. It is however clear that newly synthesized GABAB 
receptors need to be assembled within the ER into heterodimers for forward trafficking to the 
cell surface. This is due to the presence of an ER retention signal located within the C-
terminal domain of GABAB1 (Calver et al 2001, Margeta-Mitrovic et al 2000, Pagano et al 
2001a). Interaction of COPI (a constituent of the machimery for retrograde protein transport) 
with the ER retention signal of GABAB1 redirect unassembled escaped subunits from the cis-
Golgi compartment back to the ER (Brock et al 2005). Efficient forward trafficking of 
GABAB1 (in which the ER-retention signal was inactivated to permit ER exit) from the trans-
Golgi network to the plasma membrane appears to require a LL-motif located within the 
coiled-coil domain of GABAB1 (Restituito et al 2005). It is however unclear whether the LL-
motif is involed in forward trafficking of the heterodimeric receptor complex since it is most 
likely masked by the assembly with GABAB2.  
Once the receptors reach the plasma membrane their residence time is determined by its rates 
of endocytosis, recycling and degradation. It is now well established that GABAB receptors 
constitutively internalize with a high rate via the classical clathrin and dynamin-dependent 
pathway (Grampp et al 2007b, Laffray et al 2007, Vargas et al 2008). Cell surface labeling 
experiments and life cell imaging suggest that GABAB receptors in cultured neurons are 
rapidly endocytosed (50% of cell surface receptors are internalized within 2-10 min) (Hannan 
et al 2011b, Maier et al 2010b, Wilkins et al 2008) . Endocytosis of GABAB receptors involve 
the interaction with the AP2 (adapter protein 2) complex, which recruit membrane proteins to 
clathrin-coated pits (Grampp et al 2008b, Grampp et al 2007b, Vargas et al 2008). 
Internalized GABAB receptors are sorted from early endosomes either to Rab4 and Rab11-
positive recycling endosomes for reinsertion into the plasma membrane or to lysosomes for 
degradation (Grampp et al 2008b, Hannan et al 2011b, Laffray et al 2007, Vargas et al 2008). 
In addition, activation of GABAB receptors with baclofen has been shown to accelerate 
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recycling of receptors and blocking recycling diverts the receptors to lysosomes for 
degradation (Grampp et al 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Pathways of GABAB receptor trafficking. GABAB receptors are synthesized and inserted 
into the ER membrane where the subunits assemble into the heterodimeric receptor (red and blue 
boxes). They are then transported via the Golgi apparatus to the plasma membrane. GABAB receptors 
at the plasma membrane are constitutively endocytosed via the clathrin and dynamin-dependent 
mechanism. Internalized GABAB receptors are sorted from early endosomes either to recycling 
endosomes for reinsertion into the plasma membrane or to lysosomes for degradation. 
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DEGRADATION OF GABAB RECEPTORS 
There is currently only limited information available on the degradation pathways of GABAB 
receptors. Based on their intracellular accumulation upon inhibition of lysosomal protein 
degradation (Grampp et al 2008a, Grampp et al 2007b, Kantamneni et al 2008a) and their 
colocalization with lysosomal marker proteins (Grampp et al 2008a, Hannan et al 2011a) 
there is no doubt that GABAB receptors are eventually degraded in lysosomes. There is first 
indications that the ESCRT (endosomal sorting complex required for transport) machinery, 
which sorts ubiquitinated proteins to lysosomes, is involved in targeting GABAB receptors to 
lysosomes. Knockdown of the ESCRT protein TSG101 (tumor susceptibility gene 101) 
prevented degradation of GABAB receptors (Kantamneni et al 2008a).  
Lysosomal degradation and recycling of GABAB receptors need to be tightly regulated to 
ensure the correct number of receptors at the cell surface. There is evidence that both 
mechanisms are interconnected and influence each other. For instance, inhibition of receptor 
recycling redirected the receptors to lysosomes for degradation (Grampp et al 2008). 
Furthermore, sustained activation of glutamate receptors (a condition that occurs in brain 
ischemia) rapidly down-regulates GABAB receptors by shifting the recycling/degradation 
balance toward lysosomal degradation (Guetg et al 2010, Kantamneni et al 2014, Maier et al 
2010b, Terunuma et al 2010). However, the precise signals regulating GABAB receptor 
degradation as well as the contribution of alternative degradation pathways such as 
proteasomal degradation are unknown. 
 
MECHANISMS OF PROTEIN DEGRADATION 
The precise regulation of degradation is fundamental for almost all cellular processes. 
Accordingly, eukaryotic cells have evolved complex machineries for protein degradation 
(Ciechanover 2006). The major proteases in eukaryotic cells are confined to specialized 
organelles (lysosomes) and protein complexes (proteasomes) (Fig. 3). The vast majority of 
plasma membrane proteins are degraded in lysosomes, which are heterogeneously shaped 
vacuoles containing lysosomal hydrolases for protein degradation (Saftig & Klumperman 
2009). In contrast, most soluble and intracellular membrane proteins are degraded by 
proteasomes (Goldberg 2007, Hicke 2001).  
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Figure 3. Mechanisms of protein degradation. Proteins are degraded either by proteasomes (left) or 
lysosomes (right). Sorting of proteins from early endosomes via multivesicular bodies (MVB) to 
lysosomes involves ubiquitination of the target protein with either a single ubiquitin to one or multiple 
sites of a substrate protein (mono or multiple mono-ubiquitination) or with K63-linked polyubiquitin. 
K48-linked polyubiquitination is usually required for proteasomal degradation. The figure was taken 
from (Ciechanover 2005) 
 
Ubiquitin tags proteins for lysosomal and proteasomal degradation 
Ubiquitin is a 76-amino acid residue protein with a size of 8 kDa, which serves not only as a 
signal for proteasomal degradation but is also a sorting signal for the regulation of protein 
transport between membrane compartments. In a process called ubiquitination, ubiquitin is 
covalently attached to lysine (K) residues of the target protein (Hershko & Ciechanover 
1998). The conjugation of ubiquitin to the target protein requires three enzymes (Fig. 4): an 
ubiquitin-activating enzyme (E1), an ubiquitin-conjugation enzyme (E2) and an ubiquitin 
ligase (E3). Ubiquitin is first activated by the E1 enzyme in an ATP-dependent reaction by 
formation of a thiolester bond with this enzyme and is then transferred to the E2 enzyme. In 
the final step the E3 enzyme links the C-terminal glycine of ubiquitin to a lysine side chain of 
the substrate protein by forming a stable isopeptide bond (Hershko & Ciechanover 1998). 
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There are several ways how proteins can be modified by ubiquitin. The simplest one is 
monoubiquitination, where a single ubiquitin is attached to a target protein (Hicke et al., 
2004). Another modification is multiple-ubiquitination, where multiple single ubiquitin 
molecules are attached to several lysine residues in the target protein. Finally, polyubiquitin 
chains can be attached to the target protein. These polyubiquitin chains are formed by the 
conjugation of the ubiquitin C-terminus to one of the seven lysine residues (K6, K11, K27, 
K29, K33, K48 and K63) of another ubiquitin (Pickart and Fushman, 2004; Ikeda and Dikic, 
2008) (Fig. 3). Polyubiquitin chains linked via K48 and via K63 both function as a signal for 
degradation but via different routes. K48-linked chains mark proteins for proteasomal 
degradation (Chau et al 1989, Hershko & Ciechanover 1992, Weissman 2001), whereas K63-
linked chains serve as a signal for sorting internalized plasma membrane proteins to 
lysosomes via the multivesicular body (MVB) pathway (Duncan et al 2006, Huang et al 2006, 
Lauwers et al 2009, MacGurn et al 2012). 
 
 
 
 
 
Figure 4: The ubiquitin pathway. Ubiquitination comprises three subsequential enzymatic reactions. 
In step 1, free ubiquitin is activated by an ubiquitin-activating enzyme (E1) via an ATP-dependent 
reaction. In step 2, the activated ubiquitin is transferred to a cysteine of an ubiquitin-conjugating 
enzyme (E2) via a thioester linkage. In step 3, an ubiquitin ligase (E3) couples the ubiquitin to a lysine 
residue in the substrate through an isopeptide bond. The transfer of ubiquitin to the substrate is either 
mediated by the E3 enzyme (in the case of the HECT E3 family) or directly by E2 enzym (in the case 
of RING E3 family). The figure was taken from (Mabb & Ehlers 2010a). 
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Proteasomes and the endoplasmic reticulum-associated degradation 
(ERAD) pathway 
Proteasomes are composed of two multiprotein complexes: the 20S core complex and the 19S 
regulatory complex. The 20S core complex is composed of four heptameric rings of α and β 
subunits and contains the proteolytic activity. The 19S complex recruits the polyubiquitylated 
protein, removes the ubiquitin and, using ATPase activity, unfolds the protein for 
translocation into the 20S chamber (Dahlmann 2005). Structurally, the 19S regulatory 
complex contains a hexameric ring of AAA-ATPases and ~12 non-ATPase subunits (Bochtler 
et al 1999, Tanahashi et al 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Proteasome structure. The proteasome is a multiprotein assembly containing the 20S 
core complex and the 19S regulatory complex. The 20S complex is a hollow cylinder composed of 
two outer -rings and two inner -rings, which contains the proteolytic activity. The 19S regulatory 
complex consists of a hexameric ring of AAA-ATPases and ~12 non-ATPase subunits (Adams 
2003). 
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Proteasomal degradation of membrane proteins is mediated via the ERAD pathway. The most 
well established function of ERAD is the elimination of newly synthesized membrane 
proteins present in the ER, which are damaged or misfolded (Petaja-Repo et al 2001). This 
process is initiated by recognition of the protein to be degraded and can take place through 
different pathways. For example, it can be a result of a too long association with ER 
chaperones or of a modified glycan handling (Parodi 2000, Trombetta & Parodi 2003). Once 
the membrane protein is selected for ERAD, it is removed from the ER membrane into the 
cytoplasm by a process called retrotranslocation, which involves the action of multiple 
proteins (Fig. 5). First ERAD substrates are recognized by specialized UBX domain 
containing adaptor proteins and ubiquitinated by a membrane-associated E3 ligase (such as 
Hrd1). Then the ubiquitinated substrate is removed from the ER membrane in an ATP-
dependent manner by the AAA-ATPase VCP/p97 and transferred to the cytoplasm for 
degradation by the proteasome (Lilley & Ploegh 2005, Neuber et al 2005, Ruggiano et al 
2014, Schuberth & Buchberger 2005). 
 
 
 
 
Figure 6: The ERAD pathway. First, ERAD substrates are recognized by cytoplasmic and luminal 
chaperones like Hsp70-family members, calnexin or calreticulin. In a second step, the protein is 
polyubiquitinated by a membrane bound E3 ligase (e. g. Hrd1) and removed from the ER membrane to 
the cytosol by a process named retrotranslocation, involving the AAA-ATPase VCP/p97. Then the 
polyubiquitynated protein is recognized and degraded by the proteasome. The figure was taken from 
(Tsai & Weissman 2011). 
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Lysosomes and the endosomal complex required for transport (ESCRT). 
Receptors degraded via the lysosomal pathway are sorted after internalization from early 
endosomes to late endosomes and multivesicular endosomes (MVEs) and are then delivered 
to lysosomes, where they are degraded by hydrolases (Raiborg et al 2003). Sorting of an 
endocytosed  membrane protein to lysosomes is mediated by the ESCRT machinery 
(Katzmann et al 2001). The ESCRT machinery consists of four multiprotein complexes 
ESCRT-0, -I, -II and –III. They sequentially facilitate sorting of ubiquitinated proteins from 
early to late endosomes and assists in the formation of intraluminal vesicles containing the 
cargo proteins of multivesicular endosomes (Katzmann et al 2001). Upon fusion of the MVE 
with the lysosome, the intraluminal vesicles are degraded by lipases and proteases present in 
the lysosome (Saftig & Klumperman 2009). The highly complex components of the ESCRT 
machinery are structurally well-established (Raiborg & Stenmark 2009). Proteins of ESCRT-
0, ESCRT-I and ESCRT-II complexes contain ubiquitin interaction motifs (UIM), which 
allow them to interact with ubiquitin-tagged proteins (Fisher et al 2003). A specialty of the 
ESCRT machinery is its ability to form vesicles that bud into the endosome lumen. ESCRT-
III, recruited by ESCRT-II, is thought to be mainly involved in this process of “inward 
budding” (Raiborg & Stenmark 2009). In addition, ESCRT-III recruits deubiquitinating 
enzymes (DUBs), which are important for recycling of ubiquitin (Amerik et al 2000, 
Swaminathan et al 1999). DUBs recruited to ESCRT-0 are assumed to reverse ubiquitination 
of proteins not destined for degradation (Raiborg & Stenmark 2009).  
 
 
Figure 7: Marking and sorting of membrane proteins into intraluminal vesicles. Endocytosed 
membrane proteins are tagged with ubiquitin via an E3 Ligase. This process can be reversed via 
deubiquitinating enzymes (DUBs), which lead to cargo recycling. Ubiquitin-tagged proteins are 
recognized and clustered via the endosomal complex required for sorting (ESCRT) complexes 0, I, 
and II. ESCRT-III is supposed to be responsible for the packaging of cargo into intraluminal vesicles 
(ILVs) and their subsequent scission into the endosome. DUBs that are recruited via ESCRT-III 
recycle ubiquitin, which then can again be linked to proteins. The figure was taken from (MacGurn et 
al 2012)  
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AIMS OF THE THESIS  
The availability of GABAB receptors in the neuronal plasma membrane is determined by their 
rate of forward trafficking from the ER to the cell surface as well as their rates of endocytosis, 
recycling and degradation. Currently, there is little known about the mechansisms involved in 
degrading GABAB receptors and how they are regulated. Plasma membrane receptors can 
potentially be degraded by proteasomes or lysosomes. Differential ubiquitination is the basis 
for sorting the proteins into the two distinct pathways (Hershko & Ciechanover 1998, 
Katzmann et al 2002). While K48-linked ubiquitination is a common signal for proteasomal 
degradation, K63-linked ubiquitination often serves as a sorting signal for lysosomal 
degradation. In this thesis, we analyzed whether and under what conditions GABAB receptors 
are degraded by proteasomes and lysosomes. In addition, we tested the hypothesis that 
degradation of GABAB receptors regulates the amount cell surface receptors available for 
signaling. The research program is divided into three sub-projects: 
Study 1: Endoplasmic reticulum-associated degradation (ERAD) controls cell surface 
expression of GABAB receptors 
Here we tested whether GABAB receptors are degraded by proteasomes. We found that 
GABAB receptors in the ER are constitutively degraded by proteasomes via the ERAD 
machinery, which required K43-linked ubiquitination of K767/771 in the C-terminal domain 
of GABAB2. The data suggest that proteasomal degradation of GABAB receptors via ERAD 
determines the amount of GABAB receptors present in the ER available for forward 
trafficking to the cell surface. 
Study 2: Proteasomal degradation of GABAB receptors is mediated by the interaction of 
the GABAB2 C-terminus with the proteasomal ATPase Rpt6 and regulated by neuronal 
activity 
In this study we searched for proteins involved in proteasomal degradation of GABAB 
receptors and tested the hypothesis that proteasomal degradation may depend on the level of 
neuronal activity. We found that the C-terminus of GABAB2 interacts with the proteasomal 
AAA-ATPases Rpt6. The interaction of GABAB2 with Rpt6 and correspondingly the 
proteasomal degradation of the receptors were found to be regulated by neuronal activity. 
This mechanism adjust the amount of cell surface GABAB receptors according to the activity 
level of the neuron and most likely plays an important role in homeostatic plasticity.  
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Study 3: CaMKII-dependent K63-linked ubiquitination of GABAB1 drives lysosomal 
degradation of GABAB receptors 
Here we tested whether K63-linked ubiquitination of GABAB receptors serves as a sorting 
signal for their lysosomal degradation. We identified four lysine residues in GABAB1 which 
are required to be K63-linked ubiquitinated in a CaMKII-dependent manner for lysosomal 
degradation of GABAB receptors. The data indicate that the activity level of CaMKII 
regulates K63-linked ubiquitination of GABAB1 and thereby the rate of lysosomal degradation 
of GABAB receptors. 
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ABSTRACT  
 
Metabotropic GABAB receptors are crucial for controlling the excitability of neurons by 
mediating slow inhibition in the CNS. The strength of receptor signaling depends on the 
number of cell surface receptors, which is thought to be regulated by trafficking and 
degradation mechanisms. While the mechanisms of GABAB receptor trafficking are studied to 
some extent, it is currently unclear whether receptor degradation actively controls the number 
of GABAB receptors available for signaling. Here we tested the hypothesis that proteasomal 
degradation contributes to the regulation of GABAB receptor expression levels. Blocking 
proteasomal activity in cultured cortical neurons considerably enhanced total and cell surface 
expression of GABAB receptors, indicating the constitutive degradation of the receptors by 
proteasomes. Proteasomal degradation required K48-linked polyubiquitination of lysines 
767/771 in the C-terminal domain of the GABAB2 subunit. Inactivation of these ubiquitination 
sites increased receptor levels and GABAB receptor signaling in neurons. Proteasomal 
degradation was mediated by endoplasmic reticulum (ER)-associated degradation (ERAD) as 
shown by the accumulation of receptors in the ER upon inhibition of proteasomes, by the 
increase of receptor levels as well as receptor signaling upon blocking ERAD function and by 
the interaction of GABAB receptors with the essential ERAD components Hrd1 and p97. In 
conclusion, the data support a model in which the fraction of GABAB receptor available for 
plasma membrane trafficking is regulated by degradation via the ERAD machinery. Thus, 
modulation of ERAD activity by changes in physiological conditions may represent a 
mechanism to adjust receptor numbers and thereby signaling strength.  
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INTRODUCTION 
Signaling strength of neurotransmitter receptors is significantly controlled by the number of 
receptors in the plasma membrane. Protein synthesis, cell surface trafficking, endocytotic 
removal from the plasma membrane and degradation of the receptors need to be precisely 
balanced to maintain an appropriate level of cell surface receptors. These mechanisms thus 
provide means for adapting receptor numbers in response to plastic changes in neurons. There 
is accumulating evidence that regulated protein degradation via the ubiquitin-proteasome 
system plays an important integrative role in synaptic plasticity (Cajigas et al 2010, Hegde , 
Mabb & Ehlers 2010b). Proteasomal degradation at the endoplasmic reticulum (ER) is crucial 
for the quality control of newly synthesized receptors. Incorrectly folded and misassembled 
receptor proteins are efficiently eliminated from the endoplasmic reticulum via the ER-
associated degradation (ERAD) (Vembar & Brodsky 2008). Defective receptor proteins are 
polyubiquitinated, exported from the ER membrane and degraded by proteasomes in the 
cytoplasm. There is evidence that ERAD may also be involved in the regulation of the 
number of functional receptors in response to physiological stimuli. Prolonged activation of 
IP3 receptors, which release Ca
2+
 from the ER, down-regulates the expression of the receptors 
in ER membranes via ERAD-dependent proteasomal degradation (Wojcikiewicz et al 2009). 
This is thought to be a homeostatic response to counterbalance excessive accumulation of 
Ca
2+
 in the cytoplasm. However, it is currently unclear whether the ERAD machinery 
contributes to the regulation of the cell surface density of neurotransmitter receptors. 
GABAB receptors are G protein-coupled receptors assembled from the two subunits GABAB1 
and GABAB2. They mediate slow inhibitory neurotransmission in the CNS and are thought to 
be involved in a variety of neurological disorders (Bettler et al 2004b). It is meanwhile well 
established that GABAB receptors are endocytosed from the plasma membrane via the 
classical dynamin and clathrin-dependent pathway and are eventually degraded in lysosomes 
(Benke 2010). Lysosomal targeting appears to be mediated by the ESCRT (endosomal sorting 
complex required for transport) machinery (Kantamneni et al 2008b) that sorts mono- and 
K63-linked polyubiquitinated proteins to lysosomes (Raiborg & Stenmark 2009). It is 
currently unclear whether proteasomal degradation contributes to the regulation of GABAB 
receptors available for signal transduction. Therefore, we tested in this study the hypothesis 
that cell surface levels of GABAB receptors might be controlled by proteasomal degradation. 
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EXPERIMENTAL PROCEDURES 
 Antibodies  The following primary antibodies were used: rabbit GABAB1a,b (Grampp et al 
2008b, Maier et al 2010a) directed against the C terminus of GABAB1 (affinity-purified, 1:500 
for in-cell Western assay and immunofluorescence), rabbit GABAB2N (Grampp et al 2008b, 
Maier et al 2010a) directed against the N terminus of GABAB2 (affinity-purified, 1:250 for in-
cell Western assay and immunofluorescence, 1:50 for in situ PLA), guinea pig GABAB2 
(1:1000 for immunofluorescence in neurons and 1:4000 in HEK 293 cells, 1:1000 for Western 
blotting, Chemicon International), mouse PDI (1:1000 for immunofluorescence, Santa Cruz 
Biotechnology), mouse ubiquitin (P4D1, 1:50 for Western blotting, Santa Cruz 
Biotechnology), mouse ubiquitin Lys48-specific (clone Apu2, 1:50 for in situ PLA; 
Millipore), mouse VCP (p97) (1:50 for in situ PLA, 3E8DC11, Abcam), mouse actin (1:1000 
for in-cell Western assay, Chemicon International), mouse HA (1:500 for 
immunofluorescence, Santa Cruz Biotechnology), rabbit SYVN1/Hrd1 (1:50 for in situ PLA, 
Bioss). Secondary antibodies were coupled either to horseradish peroxidase (1:5000, Jackson 
ImmunoResearch), Alexa Fluor 488 (1:1000, Invitrogen), Cy-3 (1:500, Jackson 
ImmunoResearch), IRDye680 (1:400, Li-COR Biosciences) or IRDye800CW (1:400, Li-COR 
Biosciences). 
 Drugs – Baclofen (50 , Tocris Bioscience), betulinic acid (20 g/ml, Sigma-Aldrich), 
bicucullin (4 , Tocris Bioscience), Eeyarestatin I (5 , Chembridge), CNQX (2 , 
Tocris Bioscience), lactacystin (50 , Sigma Aldrich), MG132 (10 μM, Sigma-Aldrich), 
pyrenebutyric acid (50 , Sigma-Aldrich), SMI-UPS14 (5 , BostonBiochem), TTX (0.5 
, Tocris Bioscience). 
 Plasmids  The following cDNAs in the appropriate expression vectors were used: 
GABAB(1a) (Kaupmann et al 1997) (pcDNA1), GABAB2 (Kaupmann et al 1998) (pcI) 
(pcDNA1, GABAB plasmids were kindly provided by Dr. B. Bettler, University of Basle and 
Dr. K. Kaupmann, Novartis, Basle), ubiquitin and ubiquitin (K48R) (Lim et al 2005) (pRK5-
HA, Addgene plasmids 17604, 17608), VCP/p97-EGFP and VCP/p97(DKO)-EGFP (Tresse 
et al 2010) (pEGFP-N1, Addgene plasmids 23971, 23974). 
 Mutation of GABAB2  Lysines 767 and 771 in GABAB2 were mutated to arginines using the 
Quick change II XL site directed mutagenesis kit from Stratagene according to the 
manufacturer’s instructions. 
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 Culture and transfection of cortical neurons  Primary neuronal cultures of cerebral cortex 
were prepared from E18 embryos of time-pregnant Wistar rats as described previously 
(Grampp et al 2008b, Maier et al 2010a). Neurons were kept in culture for 12 to 17 days 
before used. Neurons were transfected with plasmid DNA using magnetofection as detailed 
by Buerli et al. (Buerli et al 2007). 
 Culture and transfection of HEK 293 cells  HEK (Human Embryonic Kidney) 293 cells 
were cultured in minimum essential medium (MEM, Invitrogen) containing 10% fetal calf 
serum (Invitrogen), 2 mM glutamine (Q, Invitrogen) and 4% gentamicin (Invitrogen). HEK 
293 cells were transfected with plasmids using the calcium phosphate precipitation method. 
 Proteasome activity assay  Neurons cultured in 96-well plates were incubated for 12 h with 
either 10  MG132, 50  lactacystin or 20  betulinic acid followed by determination 
of proteasome activity using the Proteasome Glo Chymotrypsin-like cell based assay 
(Promega) according to the manufactures instructions. 
 Immunoprecipitation and Western blotting  Immunoprecipitation of GABAB receptors 
from deoxycholate extracts of rat brain membranes and Western blotting for the detection of 
GABAB2 and ubiquitin was done as described previously (Grampp et al 2008b, Grampp et al 
2007a).  
 Immunocytochemistry and confocal laser scanning microscopy  Double labeling 
immunocytochemistry was performed with cortical neurons cultured on coverslips as 
described previously (Grampp et al 2008b, Grampp et al 2007a, Maier et al 2010a). Neurons 
were analyzed by confocal laser scanning microscopy (LSM510 Meta; Zeiss, 100x plan 
apochromat oil differential interference contrast objective, 1.4 NA) at a resolution of 1024 x 
1024 pixels in the sequential mode. Quantification of fluorescence signals and image 
processing was done as detailed in (Maier et al 2010a). Images shown represent a single 
optical layer. 
 In-cell Western assay  The in-cell Western assay was exactly done as in (Maier et al 
2010a). Neurons cultured in 96-well plates were treated with the drug to be tested for the 
indicated time at 37 °C and 5% CO2. After fixation and permeabilization, the neurons were 
incubated simultaneously with GABAB receptor and actin antibodies. Non-specific GABAB 
receptor antibody binding was determined in parallel cultures by competition using the 
respective peptide-antigen (10 g/ml). After incubation with the appropriate secondary 
antibodies the fluorescence was measured with the Odyssey Infrared Imaging System (LI-
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COR Biosciences). Specific GABAB signals were normalized to the actin signal determined in 
parallel.  
 In situ proximity ligation assay (in situ PLA)  The in situ PLA technology is a highly 
sensitive antibody-based method for the microscopic detection of protein-protein interactions 
and posttranslational protein modifications in cultured cells and tissue section (Leuchowius et 
al 2010, Soderberg et al 2006). For in situ PLA we used Duolink PLA probes and detection 
reagents according to the manufactures instructions (Olink Bioscience). The specificity of the 
PLA signal was validated for each pair of antibodies in HEK 293 cell expressing or not 
expressing GABAB receptors. In addition, in neurons omitting one of the primary antibodies 
did not generate PLA signals. 
For signal quantification, cells were imaged for GABAB receptor expression and PLA signals 
by confocal microscopy (LSM510 Meta; Zeiss, 100x plan apochromat oil differential 
interference contrast objective, 1.4 NA, resolution 1024 x 1024 pixels, sequential mode). 
GABAB receptor fluorescence intensities, PLA spots and the cell area were quantified using 
ImageJ (http://rsbweb.nih.gov/ij/). PLA signals were normalized to the GABAB receptor 
signal and the cell area. 
 Electrophysiology  Cortical neurons at 13-15 days in vitro were recorded in the whole-cell 
voltage-clamp configuration at room temperature. Total spontaneous postsynaptic currents 
(sPSCs) were recorded at a holding potential of -60 mV. Baclofen-evoked potassium currents 
were elicited using a 10 second pulse of 50  baclofen at -90 mV. Patch electrodes were 
filled with 120 mM CsCl / KCl, 10 mM EGTA, 10 mM HEPES (pH 7.4), 4 mM MgCl2, 0.5 
mM GTP and 2 mM ATP. Spontaneous PSCs recordings were performed using intracellular 
CsCl, whereas the potassium currents were recorded using an intracellular solution containing 
KCl. The external solution contained 140 mM NaCl, 10 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 
10 mM HEPES pH 7.4 and 10 mM glucose. Potassium currents were recorded in the presence 
of TTX (0.5 μM), CNQX (2 μM) and bicuculline (4 μM). To enhance the amplitude of the 
baclofen-evoked currents, the potassium concentration of the extracellular solution was 
increased to 30 mM and the sodium concentration was reduced to 120 mM (to keep 
osmolarity constant) before the application of the GABAB agonist. All the synaptic events 
displaying amplitudes above the background noise (5-12 pA) were identified and analyzed 
off-line using MiniAnalysis 6.0.7 software (Synaptosoft). Mean amplitudes and frequency 
values were obtained from 1 min epoch’s recordings on each experimental condition and 
normalized to the control condition of the individual neuron.  
  
26 
 
 Statistical analysis  Data are presented as mean ± S.E.M.. The statistical analysis of data 
was performed with the GraphPad Prism 5 software. Unpaired t-test was used for comparing 
two conditions and one way ANOVA followed by Dunnett’s post-hoc test for analysis of 
multiple conditions. The level of significance and n values are indicated in the figure legends. 
Differences were considered statistically significant when p< 0.05. 
 
RESULTS 
 The expression level of GABAB receptors is controlled by proteasomal degradation. It is 
currently unknown whether the ubiquitin-proteasome system contributes to the regulation of 
GABAB receptor expression levels in neurons. To gain evidence for a potential degradation of 
GABAB receptors by proteasomes, we treated cultured cortical neurons for 12 h with the 
proteasome inhibitors MG132 or lactacystin and determined the GABAB1 and GABAB2 
protein expression levels. Under these conditions, MG132 and lactacystin decreased 
proteasomal activity to 31±2% and 17±1% of untreated controls, respectively (Fig. 1A). Both 
drug treatments increased total GABAB receptor expression levels (MG132, GABAB1: 
131±2 %, GABAB2: 143±5 %; lactacystin, GABAB1: 142±4 %, GABAB2: 147±2 % of control; 
Fig. 1B), suggesting that under basal conditions GABAB receptors were constitutively 
degraded to a certain extent by proteasomes. 
 Prolonged inhibition of proteasomes depletes the pool of free ubiquitin (Melikova et al 
2006, Patnaik et al 2000), which might also affect ubiquitin-dependent processes unrelated to 
proteasomal degradation. There is some evidence that GABAB receptors are sorted to 
lysosomes via the ubiquitin-dependent ESCRT (endosomal sorting complex required for 
transport) machinery (Kantamneni et al 2008b). Hence, prolonged inhibition of proteasomes 
might indirectly compromise lysosomal degradation of the receptors. However, an indirect 
contribution of lysosomal degradation could be ruled out. Pharmacologically increasing 
proteasome activity by treating cortical neurons for 12 h with the proteasome activator 
betulinic acid (Huang et al 2007), which enhanced proteasomal activity to 143±17% of 
control (Fig. 1A), significantly decreased GABAB receptor levels (GABAB1: 69±2%, 
GABAB2: 64±3% of control; Fig. 1C). 
 It has recently been shown that inhibition of the proteasome-associated deubiquitinating 
enzyme USP14 enhanced the degradation of proteasome substrates (Lee et al 2010). 
Inhibition of USP14 by incubation of cortical neurons with SMI-USP14 (small molecule 
inhibitor of USP14) strongly reduced GABAB receptor levels (GABAB1: 49±4%, GABAB2: 
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29±2% of control, Fig. 1D), further supporting the view that GABAB receptors are degraded 
by proteasomes. 
 Finally, we assessed the functional consequences of decreased GABAB receptor levels after 
enhancing proteasomal activity with betulinic acid by measuring spontaneous synaptic 
activity in electrophysiological experiments. Activation of GABAB receptors with the 
selective agonist baclofen considerably decreased the amplitude as well as the frequency of 
spontaneous postsynaptic currents (sPSCs) to 43±4% and 56±7%, respectively (Fig. 1E). 
Treatment of cultures for 12 h with betulinic acid diminished baclofen-induced inhibition of 
sPSCs (amplitude: from 43±4% to 90±12% of control, frequency: from 56±7% to 94±15% of 
control; Fig. 1E), supporting the hypothesis that enhanced proteasomal activity leads to 
reduced levels of functional GABAB receptors available for neuronal inhibition. 
 
 
 
 
FIGURE 1. The expression level of GABAB receptors is controlled by proteasomes.  
A, Verification of drug effects on proteasome activity. Neurons were incubated for 12 h with the 
indicated drugs and tested for proteasome activity. n=12 cultures; **, p<0.01, ANOVA. 
B, Blocking proteasome activity increased the level of GABAB receptors. Neurons were incubated for 
12 h with drugs and GABAB receptor levels were determined using the in-cell Western assay. 
Untreated neurons served as a control. n=40 cultures, **, p<0.01; ***, p<0.001, ANOVA. 
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C, Enhancing proteasome activity decreased the level of GABAB receptors. Neurons were incubated 
for 12 h with betulinic acid, followed by determination of GABAB receptor levels using the in-cell 
Western assay. n=40 cultures, ***, p<0.0001, t-test. 
D, Inhibition of the deubiquitinating enzyme USP14 decreased the expression level of GABAB 
receptors. Neurons were incubated for 12 h with SMI-USP14 (USP14) and tested for GABAB1 and 
GABAB2 levels using the in-cell Western assay. n=20-27 cultures, ***, p<0.0001, t-test. 
E, Enhancing proteasome activity diminished baclofen-induced inhibition of spontaneous postsynaptic 
currents (sPSCs). Left: Representative current traces showing sPSCs recorded from untreated cultured 
cortical neurons or from neurons treated for 12 h with betulinic acid. Right: Normalized amplitude and 
frequency values of the sPSCs. Mean amplitudes and frequency values were normalized to the control 
condition of the individual neuron. Con.: control, bac.: baclofen, betu.: betulinic acid. n=6, *, p < 0.05, 
t-test. 
 
GABAB receptors undergo K48-linked polyubiquitination. K48-linked polyubiquitination of 
proteins serves as a signal for proteasomal degradation. Consistent with poly-ubiquitination, 
GABAB receptors immunoprecipitated from deoxycholate extracts of crude rat brain 
membranes exhibited on Western blots ubiquitin immunoreactivity in the high molecular 
range (Fig. 2A). This suggests that GABAB receptors are ubiquitinated under basal conditions 
to a certain extent. Likewise, using the in situ proximity ligation assay (PLA), we found that 
GABAB receptors in cultured cortical neurons display K48-linked polyubiquitination, which 
was considerably increased upon inhibition of proteasomal activity with MG 132 (172±11% 
of control, Fig. 2B). This indicates the accumulation of K48-linked polyubiquitinated GABAB 
receptors destined for proteasomal degradation. 
 Next we tested whether preventing K48-linked polyubiquitination affects GABAB receptor 
levels. Over-expression in neurons of a K48-chain elongation-defective ubiquitin mutant, in 
which lysine (K) 48 had been exchanged for an arginine (R) (Ub(K48R)), considerably 
increased the level of GABAB receptors (GABAB1: 166±7%, GABAB2: 140±7% of control, 
Fig. 2C). This finding corroborates a K48-linked polyubiquitin-mediated proteasomal 
degradation of GABAB receptors. 
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Figure 2. K48-linked ubiquitination controls the expression level of GABAB receptors. 
A, Demonstration of ubiquitination of native GABAB receptors. GABAB receptors were 
immunoprecipitated from deoxycholate extracts of rat brain membranes using either GABAB1a,b or 
GABAB2N antibodies. The immunoprecipitate was subjected to Western blotting for detection of 
GABAB2 and ubiquitin. The high molecular smear detected with the ubiquitin antibody is typical for 
polyubiquitinated proteins. The ubiquitin signal in the GABAB1 immunoprecipitate was considerably 
weaker than in the GABAB2 immunoprecipitate because the GABAB1a,b antibody beads were less 
efficient in precipitating GABAB receptors than the GABAB2 antibody beads. Specificity of the 
immunoprecipitation was verified with non-immune antibodies (control). IP, immunoprecipitate; Ab, 
antibody. 
 
The C-terminal domain of GABAB2 contains a major K48-linked polyubiquitination site . 
An in silico analysis predicted two lysines in the C-terminal domain of GABAB2 at position 
767 and 771 as likely candidates for ubiquitination. We inactivated these potential 
ubiquitination sites by exchanging both lysines for arginines (GABAB2(RR)) (Fig. 3A). Upon 
transfection into HEK 293 cells, GABAB2(RR) displayed reduced K48-linked 
polyubiquitination (61±6% of wild type; Fig. 3B), indicating that K767/771 is a main site for 
K48-linked polyubiquitination in GABAB2. 
 We then tested whether GABAB1 is also a target for K48-linked polyubiquitination. 
However, HEK 293 cells transfected with GABAB1 showed only marginal GABAB1/K48-
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linked ubiquitination PLA signals as compared to HEK 293 cells expressing GABAB1 and 
GABAB2 (12±6%, Fig. 3C). In line with this finding, coexpression of GABAB1 with 
GABAB2(RR) yielded a similar reduction in GABAB receptor/K48-linked polyubiquitination 
signals (56±8%, Fig. 3C) as observed for GABAB2(RR) alone (61±6%, Fig. 3B). Thus, 
GABAB2 appears to be the main target for K48-linked polyubiquitination of GABAB 
receptors. 
 Over-expressing GABAB2(RR) in cultured neurons increased GABAB receptor levels to a 
similar level as observed after chronic proteasome inhibition (GABAB1: 152±15%, GABAB2: 
146±9% of control; Fig. 3D). This suggests that K767/771 in GABAB2 is the major K48-
linked polyubiquitination site required for proteasomal degradation of GABAB receptors. 
 The functional consequence of the increased GABAB2 cell surface density after transfecting 
neurons with GABAB2(RR) was analyzed by measuring baclofen-induced K
+
 currents using 
whole-cell patch-clamp recordings. Transfection of GABAB2(RR) in neurons resulted in 
2.8±0.6-fold increased K
+
 channel current amplitudes after activation of GABAB receptors 
with baclofen as compared to neurons transfected with wild type GABAB2 (Fig. 3E). Thus, 
preventing proteasomal degradation of GABAB2 by over-expression of GABAB2(RR) 
increased the number of functional cell surface GABAB receptors available for signaling. 
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FIGURE 3. The C-terminal domain of GABAB2 contains a major K48-linked ubiquitination site. 
A, Scheme depicting the location of mutated lysines in GABAB2. 
B, Decreased K48-linked polyubiquitination of a GABAB2 mutant in which lysines 767 and 771 had 
been changed to arginines (GABAB2(RR)). HEK293 cells were transfected with plasmids containing 
either GABAB2 or GABAB2(RR) together with HA-Ub plasmid. Cells were analyzed by in situ PLA 
using antibodies directed against GABAB2 and K48-linked polyubiquitin to detect K48-linked 
polyubiquitinated GABAB2 (left, white dots, scale bar: 5 μm). Right: quantification of PLA signals. 
n=30 cells, ***, p<0.0001, t-test. 
C, GABAB2 is the main target for K48-linked polyubiquitination. HEK 293 cells were transfected with 
plasmids containing cDNA for ubiquitin and either GABAB1 alone, GABAB1 and wild type GABAB2 
or GABAB1 and GABAB2(RR). Cells were analyzed by in situ PLA to detect K48-linked 
polyubiquitinated GABAB receptors (left, white dots, scale bar: 5 μm). Right: quantification of PLA 
signals. n=25-30 cells, **, p<0.001, ***, p<0.0001, ANOVA. 
D, Increased GABAB receptor expression levels in neurons over-expressing GABAB2(RR). Neurons 
were co-transfected with plasmids containing GFP and GABAB2 or GFP and GABAB2(RR) and stained 
for GABAB2 (left, upper panels) or GABAB1 (left, lower panels). Right: quantification of fluorescence 
signals. n=27 (GABAB1) and 40 (GABAB2) neurons, ***, p=0.0003; t-test. Scale bar: 10 μm. 
E, Over-expression of GABAB2(RR) in neurons increased GABAB receptor-mediated K
+
 currents. 
Left: Representative traces of baclofen-induced K
+
 currents recorded in neurons transfected with wild 
type GABAB2 or GABAB2(RR). Right: Normalized K
+
 current amplitudes. Current amplitude of 
GABAB2(RR) transfected neurons were normalized to the mean of current amplitudes recorded from 
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GABAB2 transfected neurons. bac.: baclofen. n=16 for GABAB2 and n=18 for GABAB2(RR), *, p < 
0.05, t-test. 
 
Cell surface expression of GABAB receptors is regulated by ERAD. The most likely 
mechanism for proteasomal degradation of GABAB receptors is the ER-associated 
degradation (ERAD). If GABAB receptors are degraded by ERAD, inhibition of proteasomal 
activity should result in an accumulation of GABAB receptors in the ER. Indeed, blocking 
proteasomal activity in neurons for 12 h with MG132 increased the number of GABAB2 
clusters (136±6% of control) as well as the clusters co-localizing with a marker protein for the 
ER (protein disulfide isomerase [PDI], 133±7% of control, Fig. 4A). 
 To further establish the role of ERAD in regulating cellular GABAB receptor levels we 
tested the effect of directly inhibiting ERAD. Treatment of neurons for 12 h with the ERAD 
inhibitor Eeyarestatin I (EerI) (Fiebiger et al 2004, Wang et al 2008) increased both total 
GABAB2 (183±15% of control, Fig. 4B) and cell surface levels of GABAB2 (204±32% of 
control, Fig. 4C). Over-expression of GABAB2(RR), which lack the main K48-linked 
polyubiquitination sites, did not further increase total (112±7% of control, Fig. 4D) or cell 
surface GABAB receptor levels (93±15% of control, Fig. 4E). These observations indicate that 
K48-linked polyubiquitinated GABAB receptors are degraded by ERAD. 
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FIGURE 4. GABAB receptors are degraded via the ERAD pathway.  
A, Blocking proteasomal activity increased the number of GABAB2 clusters co-localized with the ER 
marker protein PDI. Neurons were incubated for 12 h with MG132 and stained for GABAB2 (red) and 
PDI (green). The yellow clusters in the merged image indicate the co-localization of GABAB2 and PDI 
(scale bars: 5 μm, 1 μm for insets). Lower panels: quantification revealed enhanced co-localization of 
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GABAB2 and PDI after proteasome inhibition. Control refers to the number of clusters in neurons not 
treated with MG132. n=25-30 neurons, ***, p<0.0001; t-test.  
B-E, Blocking the ERAD pathway increased the level of GABAB receptors. Neurons were transfected 
with plasmids containing EGFP (for detection of transfected neurons) and either wild type GABAB2 
(B, C) or GABAB2(RR) (D, E). After 48 h cultures were incubated for 12 h with or without (controls) 
the ERAD blocker Eeyarestatin I (EerI). Total (B, D) and cell surface (C, E) GABAB receptor levels 
were determined immunocytochemically using GABAB2 antibodies (red, upper panels). Scale bars: 10 
μm. Lower panels: quantification of GABAB2 fluorescence signals. n=28-30 neurons; ***, p<0.0001, 
n.s., p>0.05; t-test.  
 
 
 
 GABAB receptors interact with the ERAD E3 ubiquitin ligase Hrd1. Hrd1 is one 
prototypical ERAD E3 ubiquitin ligases responsible for K48-linked polyubiquitination of 
ERAD substrates (Smith et al 2011). Using in situ PLA, we further confirmed the potential 
degradation of GABAB receptors via ERAD by showing that GABAB receptors interact with 
Hrd1 (Fig. 5A). Inhibition of ERAD for 12 h with EerI increased the number of interactions 
(GABAB2/Hrd1: 490±45%, GABAB1/Hrd1: 305±18% of control; Fig. 5A), indicating the 
accumulation of GABAB receptors at this central ERAD multiprotein complex. In line with 
this observation, blocking ERAD function for 12 h with EerI considerably increased the level 
of K48-linked polyubiquitinated GABAB receptors (242±21% of control, Fig. 5B). 
 
 
FIGURE 5. GABAB receptors interact with the ERAD E3 ligase Hrd1. 
A, Demonstration of the interaction of GABAB receptors with the ERAD E3 ligase Hrd1 using in situ 
PLA with Hrd1 and GABAB2 antibodies (left, upper panels) or GABAB1 antibodies in cortical neurons 
(left, lower panels). Treatment of neurons for 12 h with EerI strongly increased the number of 
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interactions. Right: quantification of in situ PLA signals. n=21-27 neurons, ***, p<0.0001; t-test. 
Scale bar: 5 μm. 
B, Inhibition of ERAD induced the accumulation of K48-linked polyubiquitinated GABAB receptors. 
Neurons were incubated with EerI for 12 h and analyzed for K48-linked ubiquitination using in situ 
PLA (white dots in representative images, scale bar: 5 μm). Right: quantification of in situ PLA 
signals. n=32 cells, ***, p<0.0001, t-test. 
 
 
 
GABAB receptors interact with the essential ERAD component p97. The AAA-ATPase p97 
is a central constituent of the ERAD machinery involved in the retrotranslocation of proteins 
to the cytoplasm for proteasomal degradation (Wang et al 2004). Using in situ PLA, we found 
that GABAB receptors interact with p97 (Fig. 6A). This finding further demonstrates the 
ERAD-mediated degradation of GABAB receptors. Inhibition of p97 by EerI decreased the 
interaction of GABAB2 with p97 (40±8% of control; Fig. 6A), suggesting that the association 
is activity-dependent. 
 Inhibition of p97 function in neurons by over-expression of a dominant-negative mutant of 
p97 (p97[DKO]) considerably increased total (176±11% of control, Fig. 6B) as well as cell 
surface GABAB receptor levels (143±11% of control; Fig. 6C) as compared to neurons over-
expressing wild type p97. Over-expressing in addition GABAB2(RR) did not further increase 
total (wild type p97: 100±6%, p97(DKO): 104±6%, Fig. 6D) or cell surface GABAB receptor 
levels (wild type p97: 100±12%, p97(DKO): 100±11%, Fig. 6E), indicating that 
ubiquitination of GABAB2 is required for being recognized by the ERAD machinery. 
 Whole-cell patch-clamp recordings finally verified that inhibition of ERAD function by 
over-expression of p97(DKO) increased the level of functional cell surface GABAB receptors 
(Fig. 6F). Neurons over-expressing p97(DKO) displayed considerably increased amplitudes 
of baclofen-induced K
+
 currents (control: 72±14 pA, p97(DKO): 139±14 pA; Fig. 7 F). These 
experiments show that GABAB receptors are degraded by ERAD, which affects the levels of 
total and cell surface GABAB receptors. 
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FIGURE 6. GABAB receptors interact with the ERAD AAA-ATPase p97. 
A, Demonstration of the interaction of GABAB receptors with the ERAD AAA-ATPase p97 in cortical 
neurons using in situ PLA. Treatment of neurons for 12 h with the p97 inhibitor EerI strongly reduced 
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the interaction. Left: quantification of in situ PLA signals. n=18-21 neurons, ***, p<0.0001; t-test. 
Scale bar: 5 μm. 
B-C, Disruption of ERAD function by over-expression of a dominant-negative mutant of p97 
enhanced the level of total (B) and cell surface GABAB2 receptors (C). Neurons were transfected with 
plasmids containing HA-tagged p97 or its dominant-negative mutant HA-tagged p97(DKO) and 
stained for GABAB2 (red) and HA (green). Scale bars: 10 μm. Lower panels: quantification of 
GABAB2 fluorescence signals. n=40-50 neurons, ***, p<0.0001; t-test. 
D-E, Over-expression of GABAB2(RR) in neurons transfected with wild type p97 or p97(DKO) did 
not result in an additional increase of total (D) or cell surface (E) GABAB2 levels. Neurons were 
transfected with plasmids containing GABAB2(RR) and either HA-tagged p97 or its dominant-negative 
mutant HA-tagged p97(DKO) and stained for GABAB2 (red) and HA (green). Scale bars: 10 μm. 
Lower panels: quantification of GABAB2 fluorescence signals. n=28-30 neurons; n.s., p>0.05; t-test.  
F, Disruption of ERAD by over-expression of p97(DKO) in neurons increased GABAB receptor-
mediated K
+
 currents. Neurons were transfected either with plasmids containing EGFP (control) or 
with plasmids containing p97(DKO). Left: Representative traces of baclofen-induced K
+
 currents. 
Right: K
+
 current amplitudes. n=10 for control and n=8 for p97(DKO), *, p < 0.05, t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
38 
 
DISCUSSION 
 Mechanisms controlling the cell surface density of GABAB receptors are of pivotal 
importance for determining the level of GABAB receptor-mediated neuronal inhibition. 
Because GABAB receptors control glutamatergic neurotransmission (Chalifoux & Carter 
2011a) modulation of their cell surface density is presumed to significantly contribute to 
synaptic plasticity. However, the mechanisms that control cell surface expression of GABAB 
receptors are largely unknown. In the present study, we identified proteasomal degradation 
via the ER-resident ERAD machinery as a mechanism that determines cell surface expression 
of GABAB receptors.  
 Our data indicate that a fraction of GABAB receptors in the ER is constitutively K48-linked 
polyubiqutinated and degraded by the ERAD machinery. This conclusion is based on the 
observation that blocking proteasomal activity, inhibiting ERAD function or interfering with 
GABAB receptor K48-linked polyubiquitination increased the expression levels of GABAB 
receptors in neurons. Lysines 767/771 in the C-terminal domain of GABAB2 appear to 
represent the main K48-linked polyubiquitination sites required for proteasomal degradation 
as their mutational inactivation rendered GABAB receptors largely immune to degradation. It 
is currently unclear whether K48-linked polyubiquitination of both lysines or only of K767 or 
K771 serves as a tag for proteasomal degradation. A recent proteomic study analyzing the 
ubiquitination state of rat brain synaptic proteins identified K771 in GABAB2 as being 
ubiquitinated (Na et al 2012). This observation favors K771 as the main K48-linked 
polyubiquitination site in GABAB2. 
There are several lines of evidence that in particular GABAB receptors residing in the ER are 
degraded by proteasomes via ERAD. First, upon blocking proteasomal activity the receptors 
accumulated in the ER. Second, blocking ERAD function pharmacologically or by over-
expressing a dominant-negative mutant of the AAA-ATPase p97, which mediates the 
retrotranslocation of proteins to the cytoplasm for proteasomal degradation (Wang et al 2004), 
increased GABAB receptor levels. Third, GABAB receptors interacted with the ERAD 
proteins p97 and Hrd1. Hrd1 is the prototypical ERAD E3 ligase (Smith et al 2011) and most 
likely one of the ubiquitin ligases that mediate ubiquitination of GABAB receptors because 
stalling proteasomal degradation considerably increased its interaction with GABAB receptors 
and the level of K48-linked polyubiquitinated GABAB receptors.  
 In all cases tested, GABAB1 and GABAB2 were concomitantly up- or down-regulated to a 
similar extent, suggesting that assembled GABAB receptor complexes are degraded by 
ERAD. This notion is further strengthened by the finding that 1) inactivation of the 
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ubiquitination sites in GABAB2 increased the expression levels of GABAB1 and GABAB2 as 
well as GABAB receptor-activated K
+
 current amplitudes, 2) that interfering with ERAD 
function increased GABAB receptor function (baclofen-induced K
+
 currents) and 3) that both 
GABAB1 and GABAB2 generated in situ PLA signals with the ERAD E3 ubiquitin ligase Hrd1 
although only K48-linked polyubiquitination of K767/771 in GABAB2 appears to be required 
for proteasomal degradation of the receptors.  
What might be the physiological implications of this mechanism? The most firmly established 
function of ERAD is the degradation aberrant proteins in the ER (Brodsky 2012). In addition, 
ERAD has been shown to rapidly degrade activated IP3 receptors in the ER to prevent 
excessive elevation of cytosolic Ca
2+
 concentrations (Wojcikiewicz et al 2009), indicating that 
ERAD may also contribute to the regulation of functional receptors. Because blocking ERAD 
increased the level of functional GABAB receptors and ERAD appears to degrade assembled 
heterodimeric receptors it is rather unlikely that the role of ERAD is simply the degradation of 
un- or misfolded GABAB receptor subunits. The constitutive degradation of GABAB receptors 
suggests that ERAD controls the amount of receptors available for cell surface trafficking. 
This view is supported by recent studies on the regulation of cell surface GABAA receptors. 
Chronic suppression of neuronal activity or inhibition of L-type voltage-gated calcium 
channels decreased the level of functional GABAA receptors in the neuronal plasma 
membrane by a mechanism dependent on the ubiquitination of the GABAA -
subunit and proteasome activity, most likely via the ERAD pathway (Saliba et al 2009, Saliba 
et al 2007). These findings imply that regulation of ERAD activity is a potential mechanism 
to adjust the level of functional GABAB receptors to changing physiological condition. Our 
finding that modulation of proteasomal activity up- or down-regulates the level of functional 
GABAB receptors supports this view. Interestingly, the level of proteasomal activity correlates 
with the activity state of neurons (Djakovic et al 2009). We therefore hypothesize that the 
amount of functional GABAB receptors inserted into the plasma membrane is regulated by 
neuronal activity via ERAD.  
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ABSTRACT  
Regulation of cell surface expression of neurotransmitter receptors is crucial for determining 
synaptic strength and plasticity but the underlying mechanisms are not well understood. We 
previously showed that proteasomal degradation of GABAB receptors via the endoplasmic 
reticulum (ER) associated protein degradation (ERAD) machinery determines the number of 
cell surface GABAB receptors and thereby GABAB receptor-mediated neuronal inhibition. 
Here we show that proteasomal degradation of GABAB receptors requires the interaction of 
the GABAB2 C terminus with the proteasomal AAA-ATPase Rpt6. A mutant of Rpt6 lacking 
ATPase activity prevented degradation of GABAB receptors but not the removal of Lys48-
linked ubiquitin from GABAB2. Blocking ERAD activity diminished the interaction of Rpt6 
with GABAB receptors resulting in increased total as well as cell surface expression of 
GABAB receptors. Modulating neuronal activity affected proteasomal activity and 
correspondingly the interaction level of Rpt6 with GABAB2. This resulted in altered cell 
surface expression of the receptors. Thus, neuronal activity-dependent proteasomal 
degradation of GABAB receptors by the ERAD machinery is a potent mechanism regulating 
the number of GABAB receptors available for signaling and is expected to contribute to 
homeostatic neuronal plasticity. 
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INTRODUCTION 
A prominent characteristic of neuronal plasticity is the regulation of the number of 
neurotransmitter receptors available for signaling (Turrigiano 2008). The operative process 
can include regulation of protein synthesis, cell surface trafficking, endocytotic removal from 
the plasma membrane or degradation of the receptors. It is now well recognized that protein 
degradation via the ubiquitin-proteasome system plays a key role in synaptic plasticity 
(Cajigas et al 2010, Hegde 2010, Mabb & Ehlers 2010b). For instance, pharmacological 
modulation of neuronal activity in cultured hippocampal neurons induced a remodeling of 
postsynaptic proteins, which was dependent on proteasome-mediated protein degradation 
(Ehlers 2003). On the receptor level, chronic elevation of neuronal activity has been shown to 
downregulate AMPA receptors (Fu et al 2011) and NMDA receptors (Ehlers 2003, Kato et al 
2005) in a proteasome-dependent manner as a homeostatic response. 
The most well established role for proteasomal degradation of membrane receptors is the 
quality control of newly synthesized receptors in the endoplasmic reticulum (ER). Folding 
and assembly of receptors is a rather inefficient process frequently resulting in incorrectly 
folded and misassembled proteins. Defective receptor proteins are Lys
48
-linked 
polyubiquitinated, exported from the ER membrane and degraded by proteasomes. This 
process is executed by a multiprotein machinery called ER associated protein degradation 
(ERAD) (Vembar & Brodsky 2008). In addition to its quality control function, ERAD may 
also be involved in the activity-dependent regulation of neurotransmitter receptors. For 
instance, the level of functional GABAA receptors in the plasma membrane has been shown to 
be downregulated after suppression of neuronal activity or blocking L-type voltage-gated Ca
2+
 
channels by a mechanism that involved ubiquitination of the GABAA receptor 3 subunit and 
proteasomes (Saliba et al 2009, Saliba et al 2007). Pulse-chase experiments in combination 
with inhibiting ER-Golgi transport indicated that newly synthetized GABAA receptors in the 
ER were degraded most likely by ERAD. 
The excitability of neurons is controlled, amongst others, by the G protein coupled GABAB 
receptors. GABAB receptors are heterodimers composed of the two subunits GABAB1 and 
GABAB2. They mediate slow inhibitory neurotransmission by activating K
+
 channels and 
inhibiting Ca
2+
 channels (Bettler et al 2004b). We recently showed that a fraction of GABAB 
receptors is Lys
48
-linked ubiquitinated at Lys
767/771
 located in the C-terminal domain of the 
GABAB2 subunit and constitutively degraded by ERAD (Zemoura et al 2013a). This 
mechanism controls the pool of assembled GABAB receptors in the ER destined for forward 
trafficking to the plasma membrane and consequently determines the level of GABAB 
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receptor-mediated inhibition. In this study we addressed the unresolved questions which 
proteasomal component interacts with GABAB receptors and whether ERAD-mediated 
degradation of GABAB receptors is regulated by changes in neuronal activity. 
 
EXPERIMENTAL PROCEDURES 
 Antibodies : Rabbit GABAB1a,b (Grampp et al 2008b, Maier et al 2010a) directed 
against the C terminus of GABAB1 (affinity-purified, 1.8 g/ml for immunofluorescence), 
rabbit GABAB2N (Grampp et al 2008b, Maier et al 2010a) directed against the N terminus of 
GABAB2 (affinity-purified, 2.6 g/ml for whole cell ELISA and total as well as cell surface 
immunofluorescence staining, 13 g/ml for in situ PLA), guinea pig GABAB2 (1:1000 for 
Western blotting, 1:250 for in situ PLA, Chemicon International), mouse Rpt6 (clone p45-
110, 1:1000 for immunofluorescence using HEK293 cells and 1:50 using neurons, 1:50 for 
Western blotting, 1:20 for in situ PLA, Enzo), rabbit ubiquitin Lys
48
-specific (clone Apu2, 
1:50 for in situ PLA; Millipore), rabbit ubiquitin Lys
63
-specific (clone Apu3, 1:50 for in situ 
PLA; Millipore), mouse actin (1:1000 for whole cell ELISA, Chemicon International), mouse 
HA (1:500 for immunofluorescence, 1:200 for in situ PLA, Santa Cruz Biotechnology). 
Secondary antibodies were labeled with either horseradish peroxidase (1:5000, Jackson 
ImmunoResearch), Alexa Fluor 488 (1:1000, Invitrogen), Cy-3 (1:500, Jackson 
ImmunoResearch), IRDye680 (1:400, Li-COR Biosciences) or IRDye800CW (1:400, Li-COR 
Biosciences). 
 Drugs: CNQX (6-cyano-7-nitroquinoxaline-2,3-dione, 2 M, Tocris Bioscience), D-
AP5 (50 M, Tocris Bioscience), Eeyarestatin I (5 M, Chembridge), MG132 (10 μM, 
Sigma-Aldrich), picrotoxin (PTX, 20 M, Tocris Bioscience), pyrenebutyric acid (50 M, 
Sigma-Aldrich). 
 Plasmids : rat GABAB(1a) (Kaupmann et al 1997), rat GABAB2 (Kaupmann et al 1998), 
rat GABAB2T749 (Pagano et al 2001b) (GABAB plasmids were provided by Dr. B. Bettler, 
University of Basle and Dr. K. Kaupmann, Novartis, Basle), rat GABAB2(RR) (Zemoura et al 
2013a), human HA-Rpt6 and human HA-Rpt6
(Lys196Met)
 (Kumar et al 2010) (gift from Dr. G. 
Swarup, CSIR, India), mouse p45/Rpt6 (gift from Dr. Pierre Chambon, IGBMC, University 
of Strasbourg), pGBT9PheS (gift from Dr. Gerald Radziwill and Dr. Karin Moelling, 
University of Zurich). 
 Yeast Two-Hybrid Assay : The sequence encoding the last 12 C terminal amino acids 
of rat GABAB2 was introduced into the pGBT9PheS vector (Schneider et al 1997) and used 
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for screening a human brain cDNA library (Clontech) with the Yeast two-hybrid system using 
standard techniques. 
 Culture and Transfection of HEK 293 Cells : HEK (Human Embryonic Kidney) 293 
cells were cultured in Dulbecco’s Modified Eagles Medium (DMEM, Gibco, Life 
Technologies) containing 10% fetal bovine serum (PAA) and penicillin/streptomycin (PAA). 
Plasmids were introduced into HEK 293 cells using the polyethylenimine method according 
to the jetPEI protocol (Polyplus Transfection). 
 Introduction of Peptides into HEK 293 Cells : Small synthetic peptides were 
introduced into HEK 293 cells as described in (Takeuchi et al 2006). A synthetic peptide 
comprising the last 14 C terminal amino acids of GABAB2 with 7 additional arginines for 
rendering it cell-permeable was generated (RRRRRRR-RHVPPSFRVMVSGL, GenScript). A 
peptide containing the same amino acids but in a random sequence was used as a control 
(RRRRRRR-RLGPHVRMFVSSVP, GenScript). Both peptides were biotinylated at their N 
terminus to permit detection via DyLight649-conjugated steptavidin (Jackson 
ImmunoResearch). Twenty-four hours after transfection with GABAB receptor and Rpt6 
plasmids, the HEK 293 cells were washed with PBS and incubated for 5 min with 50 μM 
pyrenebutyric acid in PBS. Then the peptide was added (final concentration 10 μM), 
incubated for 15 min followed by washing the cells two times with PBS. After the addition of 
fresh culture medium, the cells were incubated for additional 24 h at 37°C / 5% CO2 and used 
for immunofluorescence experiments. 
 Culture and Transfection of Cortical Neurons: Primary neuronal cultures of cerebral 
cortex were prepared from E18 embryos of Wistar rats as detailed previously (Grampp et al 
2008b, Maier et al 2010a). Neurons were used after 12 to 17 days in culture. Neurons were 
transfected with plasmid DNA using Lipofectamine 2000 (Invitrogen) and CombiMag (OZ 
Biosciences) exactly as described in (Buerli et al 2007). 
 Proteasome Activity Assay : Neurons cultured in 96-well plates were incubated for 12 
h with either 20 M picrotoxin or 10 M CNQX / 20 M D-AP5 followed by determination 
of proteasome activity using the Proteasome Glo Chymotrypsin-like cell based assay 
(Promega) according to the manufactures instructions. 
 Whole cell ELISA : The whole cell ELISA was exactly done as previously (Maier et 
al 2010a, Zemoura et al 2013a). Neurons cultured in 96-well plates were treated with the 
indicated drugs for 12 hours at 37 °C and 5% CO2. For determining total expression of 
GABAB receptors the neurons were fixed, permeabilized and incubated simultaneously with 
antibodies directed against GABAB2 and actin. The fluorescence signals were quantified using 
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the Odyssey imaging system. GABAB2 signals were normalized to the actin signal determined 
in parallel. 
 For cell surface staining, living neurons were incubated with GABAB2N antibodies for 
2 h at 4 °C. For normalization, the cell-permeable nuclear marker DRAQ5 (1:2000, Biostatus 
Ltd.) was used.  
 Immunoprecipitation and Western Blotting : GABAB receptors were 
immunoprecipitated from 0.5 % deoxycholate extracts of rat brain membranes followed by 
Western blotting for the detection of GABAB2 and Rpt6 as previously (Grampp et al 2008b).  
 Immunocytochemisty and Confocal Laser Scanning Microscopy : Double labeling 
immunocytochemistry on HEK 293 cells and cortical neurons was done excactly as described 
previously (Grampp et al 2008b, Maier et al 2010a). Images of cells were taken by confocal 
laser scanning microscopy (LSM510 Meta, Zeiss, 100x plan apochromat oil differential 
interference contrast objectitve, 1.4 NA or LSM700, Zeiss, 40x plan apochromat oil 
differential interference contrast objectitve, 1.4 NA) at a resolution of 1024 x 1024 pixels in 
the sequential mode. Quantification of fluorescence signals and image processing was done as 
described in (Maier et al 2010a). 
 In Situ Proximity Ligation Assay (in situ PLA) : The in situ PLA technology enables 
the microscopic detection of protein-protein interactions and posttranslational modifications 
of proteins in cells in situ (Leuchowius et al 2010, Soderberg et al 2006). The target proteins 
are detected using two primary antibodies raised in different species and a corresponding pair 
of oligonucleotide labeled species-specific secondary antibodies (PLA probes). Only when the 
two primary antibodies bound to their target proteins are located in very close proximity (< 30 
nm), specific oligonucleotides can hybridize to the PLA probes enabling a rolling-cycle-
amplification reaction that generates a long DNA strand to which specific fluorophore-labeled 
oligonucleotides are hybridized. The signal from each pair of PLA probes generates an 
individual fluorescent spot detectable by fluorescence microscopy. 
In this study in situ PLA was employed for detecting the interaction of GABAB receptors with 
Rpt6 (using mouse Rpt6 1:20 and rabbit GABAB2N 13 g/ml g/ml), HA-tagged Rpt6 with 
GABAB receptors (using mouse HA 1:200 and rabbit GABAB2N 13 g/ml), as well as for 
detecting Lys
48
-linked (rabbit ubiquitin Lys
48
-specific 1:50 and guinea pig GABAB2 1:250) 
and Lys
63
-linked (rabbit ubiquitin Lys
63
-specific 1:50 and guinea pig GABAB2 1:250) 
ubiquitination of GABAB receptors. The specificity of the PLA signal was validated for each 
pair of antibodies in HEK 293 cell expressing or not expressing GABAB receptors. In 
addition, in neurons omitting one of the primary antibodies did not generate PLA signals. 
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In situ PLA was performed using the Duolink In Situ kit (Olink Bioscience) exactly according 
to the manufacturer’s instructions. Briefly, cortical neurons grown on cover slips were washed 
with PBS, fixed with 4% paraformaldehyde for 20 min at room temperature, washed again 
with PBS and permeabilised for 10 min with 0.2% Triton X-100 in PBS. After washing again 
with PBS, the neurons were incubated with the appropriate pair of primary antibodies (diluted 
in PBS containing 3% BSA) over night at 4°C. Thereafter, the cells were washed four times 
for 5 min with PBS, followed by incubation with the PLA probes (PLA probe anti-mouse 
minus and PLA probe anti-rabbit plus or PLA probe anti-guinea pig plus, all diluted 1:5 in 3% 
BSA/PBS) for 1 hour at 37°C. After washing the cells two times for 5 min with PBS the 
ligation solution diluted 1:5 in water was added to the neurons and incubated in a pre-heated 
humidity chamber for 1 hour at 37°C. The neurons were then washed two times for 5 min 
with 10 mM Tris, pH 7.4, 0.15 M NaCl, 0.05% Tween 20. Finally, the amplification solution 
containing the fluorescently labelled oligonucleotides diluted 1:5 in water along with 
secondary antibodies for the determination of the GABAB2 expression levels was added to the 
neurons and incubated in a pre-heated humidity chamber for 100 min at 37°C. Subsequently, 
the neurons were washed two times with 0.2 M Tris, pH 7.4, 0.1 M NaCl and once with 0.002 
M Tris, 0.001 M NaCl for 1 min in the dark at room temperature and mounted on microscope 
slides with Dako Fluorescent Mounting Medium. Stained neurons were immediately analyzed 
by laser scanning confocal microscopy (LSM 510 Meta, Zeiss, 100x plan apochromat oil 
differential interference contrast objectitve, 1.4 NA). Five optical sections were taken with a 
distance of 0.3 μm and a resolution of 1024x1024 pixels.  
Quantification was done by counting the PLA spots within the soma of the neurons using the 
MacBiophotonics ImageJ software (version 1.41n). First, the area of the soma and the 
integrated fluorescence intensity of the GABAB2 signal were determined and then the PLA 
spots were counted. PLA signals were normalized to the GABAB2 signal and the area of the 
soma. 
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RESULTS 
 GABAB2 Interacts with the Proteasomal AAA-ATPase Rpt6:  We recently showed 
that the expression of total and cell surface GABAB receptors is regulated by proteasomes via 
the endoplasmic reticulum associated degradation (ERAD) (Zemoura et al 2013a). To identify 
proteins that might be involved in proteasomal degradation of GABAB receptors we screened 
a brain cDNA library with a sequence comprising the last 12 C-terminal amino acids of 
GABAB2 for interacting proteins using the yeast two-hybrid assay. One of the eight putative 
GABAB receptor-interacting proteins detected with this system, the AAA-ATPase 
Rpt6/Sug1/p45 (hereafter named Rpt6), was related to protein degradation. Rpt6 is a 
component of the 19S regulatory particle of the proteasome and has been implicated in 
recruiting proteins to proteasomes for degradation (Gianni et al 2002, Inoue et al 2006, 
Masuyama & MacDonald 1998, Rezvani et al 2012, Su et al 2000, Wang et al 2007). We 
verified the interaction of Rpt6 with native GABAB receptors by their co-immunoprecipitation 
from rat brain extracts (Fig. 1A) and by in situ PLA in cultured neurons (Fig. 1B). Moreover, 
inhibition of proteasomal activity for 30 min with MG132 considerably increased the 
interaction of Rpt6 with GABAB2 (156±19% of control, Fig. 1B), suggesting that the receptors 
are no longer degraded and remained bound to Rpt6. This finding was further corroborated by 
colocalization studies. Blocking proteasomal activity with MG132 for 30 min resulted in a 
small increase of GABAB2 clusters (120±8% of control, Fig. 1C), whereas Rpt6 clusters 
remained unchanged. However, the co-localization of GABAB2 clusters with Rpt6 clusters 
was considerably increased (193±12% of control, Fig. 1C). These results suggest that 
interaction of Rpt6 with GABAB2 mediates proteasomal degradation of GABAB receptors. 
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FIGURE 1. GABAB receptors interact with the proteasomal AAA-ATPase Rpt6. 
A, coimmunoprecipitation of GABAB receptors with Rpt6. GABAB receptors were 
immunoprecipitated from 0.5% deoxycholate extracts prepared from rat brain membranes using 
GABAB2N antibodies coupled to protein A-agarose. The extensively washed immunoprecipitate was 
subjected to Western blotting for detection of GABAB2 and Rpt6. Specificity of the 
immunoprecipitation was verified by using protein A-beads conjugated to non-immune antibodies 
(control). IP, immunoprecipitate; Ab, antibody. 
B, enhanced GABAB2-Rpt6 interaction after proteasome inhibition detected by in situ PLA (left, white 
dots). Neurons were incubated for 30 min with the proteasome inhibitor MG132 (10 μM), followed by 
in situ PLA using antibodies directed against GABAB2 and Rpt6. The images depict the PLA signals in 
the soma and proximal dendrites (outlined in white). Right: quantification of in situ PLA signals in the 
soma. Means ± S.E.M., 30-36 neurons from three experiments. Scale bar: 5 μm; **, p<0.001, t-test. 
C, increased colocalization of GABAB2 and Rpt6 after blocking proteasomal activity in proximal 
dendrites. Neurons were incubated for 30 min with the proteasome inhibitor MG132 (10 μM) and 
stained with antibodies directed against GABAB2 (red) and Rpt6 (green). Yellow clusters in the 
merged image indicate the colocalization of GABAB2 and Rpt6 (top, scale bars: 5 μm, 1 μm for insets). 
Bottom: Quantification of GABAB2 and Rpt6 colocalization after proteasome inhibition. Means ± 
S.E.M., 20-24 neurons from two experiments, *, p<0.05; ***, p<0.0001; t-test. 
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The effect of Rpt6 on GABAB receptors was analyzed in detail using coexpression 
experiments in HEK 293 cells. HEK 293 cells overexpressing Rpt6 displayed reduced levels 
of total (GABAB1: 56±3%, GABAB2: 49±3% of control; Fig. 2A) as well as cell surface 
GABAB receptors (GABAB1: 38±5%, GABAB2: 47±5% of control; Fig. 2B), indicating that 
Rpt6 mediates degradation of GABAB receptors. Co-expression of Rpt6 with individual 
GABAB receptor subunits reduced the expression level of GABAB2 (60±4% of control, Fig. 
2C) but did not affect the level of GABAB1 (Fig. 2D), demonstrating that Rpt6 specifically 
interacts with GABAB2 to downregulate GABAB receptors. This notion was further 
substantiated by the finding that the expression level of a C-terminal truncated version of 
GABAB2 (GABAB2(T749)), which does not contain the Rpt6 interaction site, was not affected 
by coexpression with Rpt6 (Fig. 2E). 
 Recently we showed that proteasomal degradation of GABAB receptors requires 
Lys
48
-linked ubiquitination of the GABAB2 C-terminal domain at Lys
767/771
 (Zemoura et al 
2013a). To analyze whether Rpt6-mediated down-regulation depends on ubiquitination of 
GABAB2 we expressed Rpt6 together with a mutant of GABAB2 in which Lys
767/771
 were 
exchanged for arginines (GABAB2(RR)) to prevent ubiquitination at these sites (Zemoura et al 
2013a). As expected, GABAB2(RR) was resistant to Rpt6-mediated down-regulation, 
verifying that Rpt6 is involved in proteasomal degradation of Lys
48
-linked ubiquitinated 
GABAB receptors (Fig. 2F). 
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FIGURE 2. Rpt6 mediates proteasomal degradation via interaction with the C terminus of 
GABAB2. 
HEK 293 cells were transfected with plasmids containing GABAB1a and GABAB2 (A, B), GABAB2 or 
GABAB1a alone (C, D), a truncated version of GABAB2 (GABAB2T749) lacking the intracellular 
located C-terminal domain (E), or GABAB2(RR), a GABAB2 mutant with inactivated Lys
48
-linked 
ubiquitination sites required for proteasomal degradation (F) without (left panels, -Rpt6) or with Rpt6 
plasmid (right panels, +Rpt6). Forty-eight hours after transfection, the cells were stained for the 
indicated GABAB receptor subunit (left, representative images) and Rpt6 (not shown). Right panels: 
quantification of GABAB receptor staining levels. Means ± S.E.M., 23-120 cells from 2-4 
experiments. ***, p<0.0001; t-test. Scale bar: 10 μm.  
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Finally, to prove that Rpt6-mediated downregulation of GABAB receptors in fact depends on 
interaction of GABAB2 with Rpt6, we used a synthetic peptide (R2C-Pep) comprising the last 
14 C-terminal amino acids of GABAB2 to disrupt the GABAB2/Rpt6 interaction. R2C-Pep 
inhibited the downregulation of GABAB2 by Rpt6 (108±6% of control, Fig. 3), whereas a 
control peptide (R2r-Pep, random order of the same amino acids) had no significant effect 
(80±4% of control, Fig. 3). 
 These findings indicate that proteasomal degradation of GABAB receptors depends on 
ubiquitination of GABAB2 and is mediated by the interaction of the GABAB2 C terminus with 
Rpt6. 
 
 
FIGURE 3. A peptide comprising the last 14 C-terminal amino acids of GABAB2 blocked the 
Rpt6-mediated downregulation of GABAB2. 
Twenty-four hours after transfection of HEK 293 cells with plasmids containing GABAB2 or GABAB2 
and Rpt6 (+Rpt6) a peptide comprising the last 14 C-terminal amino acids of GABAB2 (R2C-Pep) or a 
peptide containing the same amino acids but in a random sequence (R2r-Pep) was added. After 
additional 24 h, the cells were stained for GABAB2 (left), Rpt6 (not shown) and the peptide (not 
shown). Left: Representative images (scale bar: 10 m). Right: quantification of total GABAB2 
staining. GABAB2 staining in HEK 293 cells only expressing GABAB2 (GABAB2) was taken as 
control. Means ± S.E.M., 90-110 cells from three experiments. **, p<0.01; ***, p<0.001; one way 
ANOVA, Dunnett’s post-hoc test. 
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Intact ATPase Activity of Rpt6 is Required for Proteasomal Degradation of GABAB 
Receptors: All six proteasomal AAA-ATPases, including Rpt6, are involved in substrate 
recognition, unfolding and translocation of proteins into the barrel shaped destruction 
chamber of the 20S proteasome (Sledz et al 2013). To test whether ATPase activity of Rpt6 is 
required for degradation of GABAB receptors in their native environment, we transfected 
neurons with either EGFP (control), Rpt6 or a mutant of Rpt6 (Rpt6(DN)) which lacks 
ATPase activity (mutation of Lys196 to Met) (Kumar et al 2010) and tested for total and cell 
surface expression of GABAB receptors (Fig. 4). Unlike overexpression of Rpt6 in HEK 293 
cells, transfection of neurons with Rpt6 did not reduce total (Fig. 4A) or cell surface (Fig. 4B) 
expression of GABAB receptors. This might be due to a lower level of overexpression in 
neurons, a saturation of proteasomes with Rpt6 in neurons or to the different cellular 
environment. However, transfection of neurons with Rpt6(DN) significantly increased both 
total (150±7% of control, Fig. 4A) and cell surface (157±8% of control, Fig. 4A) GABAB 
receptors. This finding indicates that ATPase activity of Rpt6 is required for constitutive 
proteaseomal degradation of GABAB receptors. 
 To test whether the loss of proteasomal degradation of GABAB receptors in neurons 
expressing Rpt6(DN) was based on the impaired ATPase activity or on a potential inability of 
GABAB2 to interact with the mutant Rpt6, we transfected neurons with either Rpt6 (control) 
or Rpt6(DN) and tested for interaction with GABAB2 using in situ PLA. The number of 
interactions were similar (statistically not different) in neurons expressing wild type Rpt6 or 
Rpt6(DN) (Fig. 4C), demonstrating that the reduced proteasomal degradation for GABAB 
receptors in neurons expressing Rpt6(DN) was caused by the impaired ATPase activity of 
Rpt6(DN).  
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FIGURE 4. Intact ATPase activity of Rpt6 is required for degradation of GABAB receptors. 
A-B, inactivation of ATPase activity of Rpt6 increased GABAB receptor expression levels. Neurons 
were transfected with either wild type Rpt6 or a non-functional mutant of Rpt6 (Rpt6(DN)) lacking 
ATPase activity. After 48 h, neurons were tested for total (A) and cell surface (B) expression of 
GABAB2 by immunofluorescence staining. Left: Representative images (scale bar: 5 m). Right: 
quantification of immunofluorescence signals. Means ± S.E.M., 30 neurons from 3 experiments. ***, 
p<0.0001; one way ANOVA, Dunnetts post-hoc test. 
C, the GABAB2/Rpt6 interaction is independent of Rpt6 ATPase activity. Neurons transfected with 
either wild type Rpt6 or Rpt6(DN) were tested for interaction of GABAB2 with Rpt6 by in situ PLA. 
Left: Representative images depicting PLA signals (white dots, scale bar: 5 m). Right: quantification 
of in situ PLA signals. Means ± S.E.M., 23 neurons from three preparations. ns, p>0.05; t-test. 
 
 
Proteins destined for proteasomal degradation are usually tagged with Lys
48
-linked 
polyubiquitin. After binding to the proteasome the protein is deubiquitinated by Rpn11 
present in the 19S regulatory particle, unfolded by the proteasomal AAA-ATPases located at 
the base of the 19S regulatory particle and thread into the 20S proteasome for degradation 
(Sorokin et al 2009). Because Rpn11 activity is unlikely to be affected in neurons transfected 
with Rpt6(DN) we expected GABAB receptors bound to Rpt6(DN) to be deubiquitinated 
although they cannot be translocated into the degradation chamber of the 20S proteasome. 
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Using in situ PLA, we indeed detected a strongly reduced level of Lys
48
-linked ubiquitinated 
GABAB receptors in neurons expressing Rpt6(DN) (39±3% of control, Fig. 5A). In contrast, 
Lys
63
-linked ubiquitination of GABAB receptors, which is not involved in proteasomal 
degradation, was not affected in Rpt6(DN) expressing neurons (Fig. 5B). 
 These experiments indicate that GABAB receptors bound to Rpt6 are deubiquinated 
but cannot be degraded if the ATPase activity of Rpt6 is impaired.  
 
 
 
FIGURE 5. Inactivation of Rpt6 reduced the fraction of Lys
48
-linked ubiquitinated GABAB 
receptors. 
Neurons were transfected with either wild type Rpt6 or a non-functional mutant of Rpt6 (Rpt6(DN)) 
lacking ATPase activity. After 48 h, neurons were fixed, permeabilized and tested for Lys
48
 (A) and 
Lys
63
-linked ubiquitination (B) of GABAB receptors using in situ PLA. Left: Representative images 
depicting the PLA signals (white dots, Scale bar: 5 m). Right: quantification of in situ PLA signals. 
Means ± S.E.M., 30 (A) and 24 (B) neurons from three preparations. ***, p<0.0001; t-test. 
 
 
 
Interaction of GABAB2 with Rpt6 is Reduced upon Blocking ERAD: We previously showed 
that GABAB receptors are constitutively degraded by proteasomes via the ERAD machinery 
(Zemoura et al 2013a). Blocking ERAD activity using the p97 inhibitor Eeyarestatin I (EerI), 
which inhibits translocation of proteins from the ER membrane to the cytoplasm for 
proteasomal degradation (Fiebiger et al 2004, Wang et al 2008), increased both total (152±6% 
of control, Fig. 6A) as well as cell surface GABAB receptors (129±6% of control, Fig. 6B), 
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confirming our previous findings. Because Eeyarestatin I targets p97, preventing ER-exit of 
ubiquitinated proteins and their interaction with the proteasomes located in the cytoplasm, we 
expected a diminished interaction of GABAB receptors with Rpt6. We employed in situ PLA 
to test whether the increase in GABAB receptors upon blocking p97 is associated with a 
decreased interaction of GABAB2 with Rpt6. Consistent with the essential role of Rpt6 for 
proteasomal degradation of GABAB receptors inhibition of p97 with Eeyarestatin I 
significantly reduced the GABAB2/Rpt6 interaction (71±4% of control, Fig. 6C). 
 
FIGURE 6. Blocking ERAD reduced GABAB2/Rpt6 interaction and increased GABAB receptor 
expression.  
A-B, blocking the ERAD pathway increased the level of GABAB receptors. Neurons grown in 96-well 
plates were incubated for 12 h with the ERAD inhibitor Eeyarestatin I (EerI, 5 μM). Total (A) and cell 
surface (B) GABAB receptor levels were determined using the whole cell ELISA and GABAB2 
antibodies. Control, cultures not treated with Eeyarestatin I. Means ± S.E.M., 30 cultures from three 
preparations. ***, p<0.0001; t-test.  
C, diminished GABAB2/Rpt6 interaction upon inhibition of ERAD. Neurons were incubated for 12 h 
with the ERAD inhibitor Eeyarestatin I (EerI, 5 μM) and analyzed for interaction of GABAB2 with 
Rpt6 using in situ PLA. Left: Representative images depicting PLA signals (white dots, scale bar: 5 
m). Right: quantification of in situ PLA signals. Means ± S.E.M., 28 neurons from three 
preparations. ***, p<0.0001; t-test. 
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Neuronal activity modulates GABAB receptor expression and GABAB2/Rpt6 interaction: 
Proteasomal activity has been reported to be regulated by the level of neuronal activity 
(Djakovic et al 2009). Therefore, we tested whether changes in neuronal activity affects the 
amount of GABAB receptor. We pharmacologically manipulated the activity of cultured 
neurons and determined their GABAB receptor protein levels using GABAB2 antibodies and 
the whole cell ELISA. Treatment of neurons for 12 h with CNQX/D-AP5 in order to block 
excitatory synaptic transmission by inhibiting AMPA and NMDA receptors considerably 
increased total and cell surface GABAB2 levels (total: 129±4%, cell surface: 135±4% of 
control, Fig. 7 A, B). In contrast, chronically blocking GABAA receptor activity with 
picrotoxin (PTX) to elevate neuronal activity decreased total as well as cell surface GABAB2 
levels (total: 72±7%, cell surface: 83±1% of control, Fig. 7 C, D). The decrease in cell surface 
GABAB2 was prevented by cotreatment with the ERAD inhibitor EerI (97±1% of control, Fig. 
7D). This finding suggests that neuronal activity regulates GABAB receptor expression levels 
via modulating proteasomal activity associated with the ERAD machinery. Under our test 
conditions, blocking AMPA and NMDA receptors reduced proteasomal activity to 62±6% of 
control neurons as determined with a luminogenic proteasome substrate (Fig. 7E). By 
contrast, blocking GABAA receptors with PTX increased protasomal activity to 169±11% of 
control neurons (Fig. 7E). These findings suggest that changes in neuronal excitation controls 
the expression level of GABAB receptors via proteasomal degradation. 
 If neuronal activity indeed regulates total and cell surface GABAB receptor expression 
via proteasomal degradation the interaction of GABAB2 with Rpt6 should be concomitantly 
regulated. Therefore, we expected a reduced level of GABAB receptor/Rpt6 interaction after 
treating neuronal cultures for 12 h with CNQX plus D-AP5, conditions that leads to 
diminished proteasome activity. Indeed, blocking glutamate receptors considerably reduced 
the level of GABAB2/Rpt6 interaction (39±4% of control, Fig. 7F). In contrast, enhancing 
neuronal activity by blocking GABAA receptors, which enhanced proteasome activity, 
increased the number of GABAB2/Rpt6 interactions (302±22% of control, Fig. 7F). These 
findings suggest that neuronal activity modulates cell surface expression of GABAB receptors 
via changes in proteasomal activity, which is reflected by changes in the level of 
GABAB2/Rpt6 interaction. 
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FIGURE 7. The expression level of GABAB receptors and interaction with Rpt6 is controlled by 
neuronal activity.  
A-D, chronic changes in neuronal activity modulate GABAB receptor expression. Neurons grown in 
96-well plates were incubated for 12 hours with 10 M CNQX/20 M D-AP5 (A, B) or with 20 M 
picrotoxin (PTX, C, D) in the absence or presence of the ERAD inhibitor Eeyarestatin I (EerI, 5 μM) 
followed by determination of total (A, C) and cell surface (B, D) GABAB2 levels using the whole cell 
ELISA. Means ± S.E.M., 20-47 cultures from 2-4 experiments. (A, B, C) **, p<0.01; ***p<0.0001; t-
test; (D) ***p<0.0001, n.s. (p>0.05); one way ANOVA, Bonferroni’s Multiple Comparison post-hoc 
test. 
E, chronic changes in neuronal activity modulate proteasome activity. Proteasome activity was 
determined in neurons grown in 96-well plates incubated for 12 h with 10 M CNQX/20 M D-AP5 
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or with 20 M picrotoxin (PTX) using the Proteasome-Glo cell-based assay. Means ± S.E.M., 12 
cultures from four preparations. **, p<0.01, one way ANOVA, Dunnett’s post-hoc test. 
F, chronic changes in neuronal activity modulate interaction of GABAB2 with Rpt6. Neurons were 
incubated for 12 hours with 10 M CNQX/20 M D-AP5 or with 20 M picrotoxin (PTX) followed 
by determination of the GABAB2/Rpt6 interaction levels using in situ PLA. Top: Representative 
images depicting the PLA signals (white dots, scale bar: 5 m). Bottom: quantification of in situ PLA 
signals. Means ± S.E.M., 37 neurons from 2 experiments. *, p<0.05, ***, p<0.0001, one way 
ANOVA, Dunnetts post-hoc test. 
 
 
DISCUSSION 
 GABAB receptors are degraded by two distinct pathways. Cell surface GABAB 
receptors are constitutively internalized via the dynamin and clathrin-dependent pathway, 
recycled to the plasma membrane and are eventually sorted to lysosomes for degradation 
(Benke 2010). Newly synthetized and assembled GABAB receptors in the ER are 
constitutively degraded to a certain extent by proteasomes via the ERAD machinery 
(Zemoura et al 2013a). This mechanism controls the pool of new GABAB receptors destined 
for forward trafficking to the plasma membrane. In the present study we show that the 
proteasomal AAA-ATPase Rpt6 interacts with the C-terminus of GABAB2 thereby mediating 
proteasomal degradation of GABAB receptors. Rpt6 is one of the six AAA-ATPases of the 
19S regulatory particle of the proteasome (Rubin et al 1996). The six distinct AAA-ATPases 
located at the base of the 19S regulatory particle of the 26S proteasome recognize, unfold, and 
translocate the protein substrates into the 20S, protein-degrading, core particle (Smith et al 
2006, Sorokin et al 2009). Initially, a yeast-two hybrid screening with a peptide comprising 
the last 12 C-terminal amino acids of GABAB2 suggested that Rpt6 may interact with 
GABAB2. Co-immunoprecipitation from rat brain extracts, colocalization in cultured neurons 
and testing the association in neurons using in situ PLA verified the interaction of Rpt6 with 
GABAB receptors. This was further substantiated by experiments inhibiting proteasome 
acitivty which increased the interaction and colocalization of Rpt6 with GABAB receptors. 
Finally, the interaction of Rpt6 with the C-terminus of GABAB2 was confirmed by peptide 
competition. 
 Experiments in HEK 293 cells support the view that Rpt6 is essential for proteasomal 
degradation of GABAB receptors. It had been previously reported that overexpression of Rpt6 
in HEK 293 cells increase proteasome activity threefold, most likely due to a regulatory role 
of free Rpt6 on proteasome assembly and thereby activity (Wang et al 2012). In line with this 
report, overexpression of Rpt6 in HEK 293 cells downregulated total and cell surface GABAB 
receptors. Downregulation depended on the Rpt6/GABAB2 interaction as well as on the Lys
48
-
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linked ubiquitination of Lys
767/771
 in GABAB2. Because Lys
767/771
 ubiquitination in GABAB2 is 
a prerequisite for proteasomal degradation of GABAB receptors (Zemoura et al 2013a) these 
findings underline that the interaction of GABAB2 with Rpt6 is required for proteasomal 
degradation of the receptors. 
 Although Rpt6 does not interact with GABAB1, as indicated by the lack of its 
downregulation when expressed in HEK 293 cells in the absence of GABAB2, GABAB1 and 
GABAB2 were concomitantly reduced to the same extent. This strongly suggests that 
assembled GABAB receptor complexes are degraded by proteasomes and is in line with our 
previous observation that heterodimeric receptor complexes are degraded by the ERAD 
machinery and not single GABAB receptor subunits before being assembled in the ER 
(Zemoura et al 2013a). Our finding that blocking ERAD function increased total and cell 
surface GABAB expression and reduced the level of GABAB2/Rpt6 interaction verifies that 
proteasomal degradation of GABAB receptors takes place at the ER. 
 Our data further indicate that proteasomal degradation of GABAB receptors in neurons 
require intact ATPase activity of Rpt6 because overexpression in neurons of a mutant Rpt6 
lacking ATPase activity led to an increase of total as well as cell surface GABAB receptors. 
This finding provides further evidence that GABAB receptors are constitutively degraded to a 
certain extent by proteasomes (Zemoura et al 2013a). Lack of ATPase activity did not affect 
the interaction of Rpt6 with GABAB2, suggesting that recruiting GABAB receptors to 
proteasomes is independent of Rpt6’s ATPase activity. 
 Proteins targeted for proteasomal degradation are deubiquitinated before being 
degraded by the 20S proteasome. Lys48-linked polyubiquitin of substrate proteins is bound by 
Rpn10 and released by the deubiquitinase activity of Rpn11 present in the 19S regulatory 
particle (Sorokin et al 2009). Overexpression of mutant Rpt6 in neurons considerably reduced 
the fraction of Lys48-linked ubiquitinated GABAB2 although the receptors were not degraded 
and remained bound to Rpt6. This suggests that deubiquitination of GABAB2 is independent 
of its degradation and takes place before or concomitant with its translocation into the 
degradation chamber of the 20S proteasome. 
 There is accumulating evidence that neuronal activity regulates proteasome-dependent 
protein degradation and, intriguingly, proteasome activity. It has recently been demonstrated 
that blockade of neuronal activity decrease proteasomal activity whereas enhancing neuronal 
activity increase proteasomal activity (Djakovic et al 2012, Djakovic et al 2009, Jakawich et 
al 2010). The mechanism of enhancing proteasomal activity involves Ca
2+
 influx via NMDA 
receptors as well as L-type voltage-gated Ca
2+
 channels (Djakovic et al 2009). This leads to 
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the activation of CaMKII which phosphorylates Rpt6 on Ser
120
 (Bingol et al 2010, Djakovic et 
al 2012, Djakovic et al 2009) to roughly double proteasomal activity (Bingol et al 2010, 
Djakovic et al 2012). Conversely, reduced neuronal activity decreases phosphorylation of 
Rpt6 (Djakovic et al 2012) resulting in diminished proteasomal activity (Djakovic et al 2009, 
Jakawich et al 2010). In view of this data, it was not surprising that blocking neuronal activity 
reduced the level of GABAB2/Rpt6 interaction and upregulated total as well as cell surface 
GABAB receptors. On the other hand, increasing neuronal activity by blocking GABAA 
receptors, which enhances proteasomal activity, increased the level GABAB2/Rpt6 interaction 
and consequently decreased the expression levels of GABAB receptors. This was reversed by 
pharmacologically blocking ERAD demonstrating that proteasomal degradation affects the 
pool of newly synthetized GABAB receptors present in the ER. These findings are in line with 
the view that the level of neuronal activity regulates proteasomal activity and thereby the pool 
of GABAB receptors available in the ER for trafficking to the plasma membrane.  
 In conclusion, our data support the hypothesis that cell surface trafficking of GABAB 
receptors is controlled by neuronal activity at the level of the ER by defining the amount of 
receptors present in the ER via regulated proteasomal degradation. This mechanism is 
expected to contribute to homeostatic synaptic plasticity. 
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Abstract  
GABAB receptors are heterodimeric G protein-coupled receptors, which control neuronal 
excitability by mediating slow and prolonged inhibition. The magnitude of GABAB receptor-
mediated inhibition essentially depends on the amount of receptors in the plasma membrane. 
One factor that determines receptor availability is regulated protein degradation. GABAB 
receptors are constitutively internalized and either recycled to the cell surface or degraded in 
lysosomes. The signal that sorts GABAB receptors to lysosomes is currently unknown. Here 
we tested whether ubiquitination is the lysosomal sorting signal for GABAB receptors. We 
found that inhibition of lysosomal activity in cortical neurons increased total and cell surface 
GABAB receptors as well as the level of K63-linked ubiquitinated receptors. Mutational 
inactivation of four putative ubiquitination sites in the GABAB1 subunit significantly 
diminished K63-linked ubiquitination of GABAB receptors and prevented their lysosomal 
degradation. Searching for factors that control lysosomal degradation of GABAB receptors 
revealed that blocking Ca
2+
/calmodulin-dependent protein kinase II (CaMKII) decreased K63-
linked ubiquitination of GABAB receptors and inhibited lysosomal degradation of GABAB 
receptors by sorting the receptors to the recycling pathway. Finally, triggering lysosomal 
degradation of GABAB receptors by sustained activation of glutamate receptors, a condition 
mimicking in brain ischemia, was accompanied with a massive increase of CaMKII-
dependent K63-linked ubiquitination of GABAB receptors. Preventing K63-linked 
ubiquitination by blocking CaMKII, overexpressing ubiquitin mutants or mutant GABAB 
receptors deficient in GABAB1 K63-linked ubiquitination prevented down-regulation of the 
receptors. These findings indicate that CaMKII-dependent K63-linked ubiquitination of 
GABAB1 at multiple sites controls sorting of GABAB receptors to lysosomes for degradation 
under physiological and pathological condition. 
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Introduction 
GABAB receptors are heterodimeric G protein-coupled receptors assembled from GABAB1 
and GABAB2 subunits. They are activated by γ-aminobutyric acid (GABA), the main 
inhibitory neurotransmitter in the brain. GABAB receptors are abundantly expressed in pre- 
and postsynaptic compartments of inhibitory as well as excitatory neurons to regulate their 
excitability. At presynaptic locations, GABAB receptors suppress neurotransmitter release 
mainly by inhibiting voltage-gated Ca
2+
 channels whereas at postsynaptic sites they induce 
slow inhibitory postsynaptic currents by activating Kir3-type K
+
 channels (Benke et al 2012). 
GABAB receptors are involved in the regulation of all main brain functions ranging from 
synaptic plasticity (Pinard et al 2010), neuronal network activity (Craig & McBain 2014, Kohl 
& Paulsen 2010) to neuronal development (Gaiarsa & Porcher 2013). Accordingly, 
dysfunction of GABAB receptor signalling has been implicated in a variety of neurological 
disorders (Benarroch 2012, Bowery 2006, Cryan & Kaupmann 2005, Kumar et al 2013). 
For understanding the contribution of GABAB receptors to physiological and pathological 
mechanisms the elucidation of its regulation is essential. A main factor regulating GABAB 
receptor signalling is the dynamic control of their cell surface expression. In this respect, 
protein degradation is one important mechanism that regulates the number of GABAB 
receptors at the cell surface. For instance, the amount of GABAB receptors in the endoplasmic 
reticulum (ER) available for forward trafficking to the cell surface is determined by the rate of 
their proteasomal degradation via the ERAD (ER associated degradation) machinery 
(Zemoura et al 2013). Proteasomal degradation of ER residing GABAB receptors is regulated 
by neuronal activity and requires K48-linked ubiquitination of GABAB2 as well as its 
interaction with the proteasomal AAA-ATPase Rpt6 (Zemoura & Benke 2014, Zemoura et al 
2013). On the other hand, GABAB receptors at the cell surface are constitutively endocytosed 
and either recycled to the cell surface or degraded in lysosomes (Grampp et al 2008, Grampp 
et al 2007, Hannan et al 2011, Kantamneni et al 2008, Vargas et al 2008). Lysosomal 
degradation of GABAB receptors is most likely mediated via the ESCRT (endosomal sorting 
complex required for transport) machinery (Kantamneni et al 2008), which sorts ubiquitinated 
membrane proteins to lysosomes (Raiborg & Stenmark 2009). Lysosomal degradation of 
GABAB receptors appears to be tightly regulated since excessive activity of glutamate 
receptors, a condition that occurs in brain ischemia, rapidly down-regulates GABAB receptors 
by preferential sorting the receptors to the lysosomal degradation pathway at the expense of 
receptor recycling (Guetg et al 2010, Kantamneni et al 2014, Maier et al 2010, Terunuma et al 
2010).  
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The specific signal(s) that sorts GABAB receptors to lysosomal degradation under normal as 
well as pathological condition is currently unknown. Here we show that Ca
2+
/calmodulin-
dependent protein kinase (CaMKII) mediated K63-linked ubiquitination of GABAB1 at 
multiple sites targets GABAB receptors to the lysosomal degradation pathway.  
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Materials and Methods 
Antibodies. The following antibodies were used: Anti-HA mouse (1:1000 for immuno-
fluorescence, 1:200 for in situ PLA, Sigma-Aldrich), rabbit GABAB1b directed against the N-
terminus of GABAB1b (affinity-purified, 1:200 for immunofluorescence, custom made by 
GenScript) (Benke et al 1999), rabbit GABAB2 directed against the N-terminus of GABAB2 
(affinity-purified, 1:500 for immunofluorescence; custom made by GenScript) (Benke et al 
2002), guinea pig GABAB2 (1:500 for immunofluorescence; Millipore), mouse GABAB1 
(1:100 for PLA; NeuroMab), rabbit ubiquitin K48-specific (clone Apu2, 1:50 for in situ PLA; 
Millipore), rabbit ubiquitin K63-specific (clone Apu3, 1:50 for in situ PLA; Millipore), goat 
Rab7 (1:250 for immunofluorescence; Santa Cruz Biotechnology), mouse Rab11 (1:40 for 
immunofluorescence; BD Transduction Laboratories). Secondary antibodies were labeled 
with either Alexa Fluor 488 (1:1000, Invitrogen), Cy-3 (1:500, Jackson ImmunoResearch 
Laboratories) or Cy-5 (1:300, Jackson ImmunoResearch Laboratories). 
 Drugs. The following chemicals were used for this study: glutamate (50 μM, Sigma-
Aldrich), KN93 (10 μM, Tocris Bioscience) and leupeptin (100 μM, Sigma-Aldrich). 
 Plasmids. The following DNAs were used: GABAB(1a) (Kaupmann et al 1997); GABAB2 
(Kaupmann et al 1998); HA-tagged ubiquitin (Addgene plasmid 17608), HA-tagged ubiquitin 
(KO) (Addgene plasmid 17603), HA-tagged ubiquitin K63 (Addgene plasmid 17606) and 
HA-tagged ubiquitin K48R (Addgene plasmid 17604) (Lim et al 2005); HA-tagged ubiquitin 
K63R was kindly provided by L-Y Liu-Chen, Temple University, Philadelphia, USA; wild 
type EGFP-tagged rab7 (Addgene plasmid 12605) and the functionally inactive mutant 
EGFP-tagged rab7(DN) (Addgene plasmid 12660) (Choudhury et al 2002); wild type EGFP-
tagged rab11 (Addgene plasmid 12674) and the a functionally inactive mutant EGFP-tagged 
rab11(DN) (Addgene plasmid 12678) (Choudhury et al 2002). 
 Mutation of GABAB1. Lysines 697, 698, 892 and 960 in GABAB1 were mutated to arginines 
using the QuikChange II XL site-directed mutagenesis kit from Stratagene according to the 
manufacturer's instructions. 
 Culture and transfection of cortical neurons. Primary neuronal cultures of cerebral cortex 
were prepared from 18 day old embryos of Wistar rats as described previously (Grampp et al 
2008). Neurons were used after 11 to 15 days in culture. Plasmid DNA was transfected into 
neurons by magnetofection using Lipofectamine 2000 (Invitrogen) and CombiMag (OZ 
Biosciences) as detailed in (Buerli et al 2007). 
 Immunocytochemistry and confocal laser scanning microscopy. Immunofluorescence 
staining was performed as described previously (Grampp et al 2008, Maier et al 2014). For 
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selective detection of cell surface GABAB receptors living neurons were incubated with 
antibodies recognizing the extracellular located N-terminal domain of GABAB1 or GABAB2 
for one hour at 4°C. For analysis of total GABAB receptors, neurons were fixed with 4% 
paraformaldehyde for 156-20 min at room temperature and permeabilized with 0.2% Triton 
X-100 before immunostaining.  
 Stained neurons were analyzed by laser scanning confocal microscopy (LSM 510 Meta, 
Zeiss). Images of eight optical sections spaced by 0.3 m were recorded with a 100x plan-
fluar oil differential interference contrast objective (1.45 NA, Zeiss) at a resolution of 1024 x 
1024 pixels. Quantitative analysis of total and cell surface staining was performed as 
described in (Maier et al 2014).  
 Quantification of colocalization of GABAB receptors with Rab7 and Rab11 was done with 
the Mac Biophotonics Image J software (JACoP plugin, “Colocalization Threshold”). This 
method of quantitative colocalization analysis of fluorescence signals is based on an 
algorithm that automatically set the thresholds for colocalization using spatial statistics and 
thus excludes bias by the experimenter (Costes et al 2004). 
 In-cell Western assay. Total GABAB receptor expression of neurons cultured in 96-well 
plates was analyzed using the in-cell Western assay exactly as described previously (Maier et 
al 2010). Fluorescence signals generated by GABAB1 and GABAB2 antibodies were 
normalized to actin signals determined simultaneously in the same cultures.  
 In situ proximity ligation assay (in situ PLA). In situ PLA is an antibody based technology 
for the detection of protein-protein interactions and posttranslational modifications of proteins 
in cells in situ (Leuchowius et al 2010, Soderberg et al 2006). The in situ PLA was performed 
using Duolink PLA probes and detection reagents (Olink Bioscience, Sigma-Aldrich) 
according to the manufacturer’s instructions as described previously (Maier et al 2014). Here 
we applied in situ PLA for the detection and quantification of GABAB receptor ubiquitination 
using mouse GABAB1 or mouse HA antibodies together with rabbit antibodies specifically 
detecting K48-linked or K63-linked ubiquitin. Quantification was done by counting individual 
in situ PLA spots using the Mac Biophotonics Image J software. The number of spots was 
normalized to the area analyzed and to the expression level of GABAB receptors. 
 Statistics. The statistical analyses were done with GraphPad Prism 5. The tests used and p 
values are given in the figure legends. Differences were considered statistically significant 
when p < 0.05. 
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Results 
Lysosomal degradation regulates cell surface expression of GABAB receptors 
GABAB receptors undergo fast constitutive dynamin and clathrin-dependent endocytosis. 
Most of the receptors are recycled to the plasma membrane whereas a minor fraction is sorted 
to the lysosomal degradation pathway (Grampp et al 2008, Grampp et al 2007, Laffray et al 
2007, Vargas et al 2008, Wilkins et al 2008). However, it is currently not known whether 
interfering with lysosomal degradation affects the expression of cell surface expression of 
GABAB receptors. Blocking lysosomal degradation in cultured cortical neurons with 
leupeptin for 12 hours considerably increased total (GABAB1, 151.4 ± 6%; GABAB2, 159.8 ± 
7% of control, Fig. 1A) as well as cell surface expression of GABAB receptors (GABAB1, 
145.9 ± 9%; GABAB2, 146.7 ± 9% of control Fig. 1B) to a similar extent. This suggests that 
constitutive lysosomal degradation is one factor determining the availability of GABAB 
receptors at the cell surface for signaling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The expression level of GABAB receptors is controlled by lysosomes 
A, The total expression level of GABAB receptors is increased in neurons after blocking lysosomal 
activity. Cortical neurons were incubated for 12 hours with 100 μM leupeptin followed by 
immunostaining for total GABAB1 and GABAB2 using the in-cell western technique. Neurons not 
treated with leupeptin served as controls. Fluorescence intensities for GABAB1 and GABAB2 in control 
neurons were set to 100%. The data represent the mean ± SEM of 30 cultures from three independent 
experiments. *** p< 0.0001; two-tailed unpaired t-test. 
B, Expression of cell surface GABAB receptors is increased in neurons after inhibiting lysosomal 
activity. Cortical neurons were treated as indicated in A and immunostained for cell surface GABAB1 
and GABAB2. Left, representative images of the soma of stained neurons. Scale bar, 5 μm. Right, the 
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graphs show the quantification of fluorescence intensities. Fluorescence intensities for GABAB1 and 
GABAB2 in control neurons were set to 100%. The data represent the mean ± SEM of 30-40 neurons 
from three independent experiments. *** p< 0.0002; two-tailed unpaired t-test. 
 
K63-linked ubiquitination is involved in lysosomal degradation of GABAB receptors 
K48-linked ubiquitination tags proteins for degradation in proteasomes whereas K63-linked 
ubiquitination is involved in non-proteolytic functions and can serve as a sorting signal for 
lysosomal degradation (Komander & Rape 2012). To test whether K63-linked ubiquitination 
is involved in lysosomal degradation of GABAB receptors neurons were transfected with a 
mutant of ubiquitin that is not able to form K63-linked chains (Ub(K63R)) and analyzed for 
cell surface expression of GABAB receptors. Inhibition of K63-linked ubiquitination by 
overexpression of Ub(K63R) increased the expression level of cell surface GABAB receptors 
(136±9% of control neurons transfected with wild type ubiquitin; Fig. 2A), suggesting that 
GABAB receptor levels are regulated by K63-linked ubiquitination. 
 Next we tested whether regulation of GABAB receptor levels by lysosomal degradation 
requires direct K63-linked ubiquitination of the receptor by in situ PLA using antibodies 
directed against GABAB1 and K63-linked ubiquitin. Under basal conditions, GABAB 
receptors exhibited K63-linked ubiquitination, which was considerably increased upon 
inhibition of lysosomal activity with leupeptin (164 ± 8 % of control, Fig. 2B). In contrast, the 
level of GABAB receptor K48-linked ubiquitination, which target the receptors to proteasomal 
degradation (Zemoura & Benke 2014, Zemoura et al 2013), remained unaffected by blocking 
lysosomal activity (Fig. 2C). This suggests that direct K63-linked ubiquitination of GABAB 
receptors regulates lysosomal degradation of GABAB receptors. 
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Figure 2. The expression level of GABAB receptors is regulated by K63-linked ubiquitination. 
A, Interference with K63-linked ubiquitination increased the expression level of cell surface GABAB 
receptors. Neurons were transfected with wild type ubiquitin (Ub) or a ubiquitin mutant unable to form 
K63-linked chains (Ub(K63R)) and analyzed for GABAB receptor expression using GABAB2 
antibodies. Left, representative images of stained neuronal somata (scale bar, 5 μm). Right, 
quantification of fluorescence intensities. The fluorescence signal of neurons transfected with wild 
type ubiquitin was set to 100%. The data represent the mean ± SEM of 34 neurons from three 
independent experiments. ** p< 0.004; two-tailed unpaired t-test. 
B, Inhibition of lysosomal activity enhanced K63-linked ubiquitination of GABAB receptors. Cortical 
neurons were incubated for 12 hour with or without (control) 100 μM leupeptin and analyzed for K63-
linked ubiquitination by in situ PLA using antibodies directed against GABAB1 and K63-linked 
ubiquitin (white dots in representative images, scale bar: 5 μm.). Right, quantification of in situ PLA 
signals. The data represent the mean ± SEM of 30-40 neurons from three independent experiments. 
*** p< 0.00001; two-tailed unpaired t-test. 
C, Inhibition of lysosomal activity did not affect K48-linked ubiquitination of GABAB receptors. 
Cortical neurons were treated as in B and analyzed for K48-linked ubiquitination by in situ PLA using 
antibodies directed against GABAB1 and K48-linked ubiquitin (white dots in representative images, 
scale bar: 5 μm.). Right, quantification of in situ PLA signals. The data represent the mean ± SEM of 
27-37 neurons from three independent experiments; n.s., p> 0.05; two-tailed unpaired t-test. 
 
Identification of K63-linked ubiquitination sites in GABAB1 
Because K63-linked ubiquitination appears to be involved in lysosomal degradation of GABAB 
receptors, we searched for potential lysine residues serving as ubiquitination sites by an in silico 
analysis of the GABAB1 sequence. Four lysines with a high probability of being ubiquitinated were 
identified: two in the cytoplasmatic loop linking transmembrane domains three and four and two in the 
C terminal domain (Fig. 3A). These sites were inactivated by mutation to arginine (K->R), resulting in 
the three GABAB1 mutants GABAB1a(K697/698R), GABAB1a(K892R) and GABAB1a(K960R). To test 
whether these sites are ubiquitinated, cultured cortical neurons were transfected with either wild type 
GABAB1a or one of the GABAB1a(K->R) mutants as well as GABAB2 and analyzed for K63-linked 
  
70 
 
ubiquitination by in situ PLA. Numerous in situ PLA signals in neurons transfected with wild type 
GABAB1a indicated that GABAB1 is K63-linked ubiquitinated under basal conditions. In contrast, all 
three mutant GABAB1a displayed strongly reduced K63-linked ubiquitination (GABAB1a(K697/698R): 
43 ± 3%, GABAB1a(K892R): 38 ± 3%, GABAB1a(K960R): 37 ±3%, of wild type GABAB1a; Fig. 3B). 
This result indicates that lysines 697 and/or 698, lysine 983 and lysine 960 in GABAB1 subunit are 
K63-linked ubiquitinated under basal conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Identification of K63-linked ubiquitination sites in GABAB1 
A, Cartoon depicting the location of K->R mutations in GABAB1. 
B, Decreased K63-linked ubiquitination of GABAB1(K->R) mutants. Cortical neurons were transfected 
with HA-tagged wildtype GABAB1a, HA-tagged GABAB1a(K697/698R), HA-tagged 
GABAB1a(K892R) or HA-tagged GABAB1a(K960R) together with wild type GABAB2 and analyzed for 
K63-linked ubiquitination by in situ PLA using antibodies directed against the HA-tag and K63-linked 
ubiquitin (white dots in representative images, the dots in the outlined area were counted for 
quantification; scale bar: 7 μm). Right, quantification of in situ PLA signals. The data represent the 
mean ± SEM of 26-35 neurons from three independent experiments. *** p< 0.0001; one way 
ANOVA, Dunnett’s Multiple Comparison 
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Ubiquitination of GABAB1 regulates cell surface expression of GABAB receptors  
To analyze the effect of K63-linked ubiquitination on cell surface expression of GABAB 
receptors, neurons were transfected either with wild type GABAB1 or GABAB1a(K->R) 
mutants along with GABAB2 and immunostained for their total and cell surface expression 
levels. Total as well as cell surface expression of all three GABAB1a mutants was considerably 
increased as compared to transfected wildtype GABAB1a (total, GABAB1a(K697/698R): 457 ± 
26%, GABAB1a(K892R): 511 ± 30%, GABAB1a(K960R): 551 ± 22%, of wild type GABAB1; 
cell surface: GABAB1a(K697/698R): 508 ± 52%, GABAB1a(K892R): 504 ± 48%, 
GABAB1a(K960R): 482.2 ± 42% of wild type GABAB1, Fig. 4A, B). Likewise, the cell surface 
expression of GABAB2 in neurons transfected with GABAB1a mutants was significantly 
increased (GABAB2 in GABAB1a (K697/698R) transfected neurons: 158 ± 14%, GABAB2 in 
GABAB1a(K892R) transfected neurons: 187 ± 17%, GABAB2 in GABAB1a(K960R) 
transfected neurons: 178 ±16% of control; Fig. 4B). The considerably lower increase in 
GABAB2 cell surface expression as compared to mutant GABAB1 was due to the fact that in 
case of GABAB1 only transfected subunits were assayed (Ha-tagged) while in the case of 
GABAB2 transfected as well as endogenously expressed subunits were detected. These results 
demonstrate that inactivation of any of the three ubiquitination sites in GABAB1 (K697/698, 
K892, K960) decreased or prevented degradation of GABAB receptors and therefore 
increased their cell surface expression. 
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Figure 4. GABAB1(K->R) mutants exhibit increased total and cell surface expression. 
A, Increased total expression levels of GABAB1a(K->R) mutants. Neurons were transfected with HA-
tagged wild type GABAB1a, HA-tagged GABAB1a(K697/698R), HA-tagged GABAB1a(K892R) or HA-
tagged GABAB1a(K960R) together with wild type GABAB2 and analyzed for the expression level of 
transfected GABAB1 using antibodies directed against the HA-tag. Left, representative images (scale 
bar: 7 μm). Right, quantification of fluorescence signals. The fluorescence signals of neurons 
transfected with wild type GABAB1 was set to 100%. The Data represent the mean ± SEM of 23-27 
neurons per experimental condition derived from three independent experiments. *** p< 0.0001; one 
way ANOVA, Dunnett’s Multiple Comparison test. 
B, Increased cell surface expression levels of GABAB1a(K->R) mutants. Neurons were transfected 
with HA-tagged wild type GABAB1a, HA-tagged GABAB1a(K697/698R), HA-tagged 
GABAB1a(K892R) or HA-tagged GABAB1a(K960R) together with wild type GABAB2 and analyzed for 
cell surface expression levels of transfected GABAB1 as well as transfected plus endogenous GABAB2 
using antibodies directed against the HA-tag and GABAB2, respectively. Left, representative images 
(scale bar: 7 μm). Right, quantification of fluorescence signals. The fluorescence signals of neurons 
transfected with wild type GABAB1 or wild type GABAB2, respectively, was set to 100%. The Data 
represent the mean ± SEM of 26-28 neurons per experimental condition derived from three 
independent experiments. ** p< 0.001; *** p< 0.0001; one way ANOVA, Dunnett’s Multiple 
Comparison test. 
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Lysosomal targeting of GABAB receptors is regulated by ubiquitination of GABAB1 
The increased total and cell surface expression levels of GABAB1a(K->R) mutants and their 
reduced K63-linked polyubiquitination suggests that ubiquitination of these lysine residues 
serve as signals for sorting the receptors to lysosomes for degradation. If this is the case, 
GABAB1a(K->R) mutants should be resistant to lysosomal degradation and their expression 
levels should not increase upon blocking lysosomal degradation. Indeed, in contrast to the 
expression level of wild type GABAB1, those of all three GABAB1a(K->R) mutants remained 
unaffected by inhibition of lysosomal degradation with leupeptin (wild type GABAB1: 249 ± 
30%, GABAB1a (K697/698R): 111 ± 5%, GABAB1a (K892R): 109 ± 5%, GABAB1a (K960R): 
108 ± 4% of control, Fig. 5A). 
 To confirm this finding, we prevented lysosomal degradation by overexpressing a 
functionally inactive mutant of the small GTPase Rab7 (Rab7(DN)). Rab7 mediates 
trafficking from early endosomes via late endosomes to lysosomes (Ng et al 2012) and 
therefore overexpression of Rab7(DN) disrupts this pathway. As expected, overexpression of 
Rab7(DN) considerably enhanced total expression of wild type GABAB1a but did not 
significantly affect the expression levels of GABAB1a(K->R) mutants (wild type GABAB1a: 
174 ± 11%, GABAB1a (K697/698R): 105 ± 8%, GABAB1a (K892R): 117 ± 8%, GABAB1a 
(K960R): 126 ± 9% of control; Fig. 5B). This indicates that preventing ubiquitination of 
specific sites in GABAB1 excluded the mutant receptors from entering the endosomal pathway 
that directs proteins to the lysosome. Therefore, our observations suggest that ubiquitination 
of multiple lysine residues in GABAB1 receptors regulates lysosomal degradation of GABAB 
receptors.  
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Figure 5. The expression levels of GABAB1a(K->R) mutants are unaffected by inhibition of 
lysosomal degradation 
A, Total expression levels of GABAB1a(K->R) mutants are unaffected by blocking lysosomal activity 
with leupeptin. Neurons were transfected with HA-tagged wildtype GABAB1a or HA-tagged 
GABAB1a(K->R) mutants together with GABAB2, incubated with 100 μM leupeptin for 12 hours 
followed by immunostaining for transfected HA-tagged GABAB1 using HA-antibodies. Left, 
representative images of untreated neurons (control, left) and of neurons incubated with leupeptin 
(right, scale bar: 7 μm). Right, quantification of fluorescence intensities. The fluorescence intensity of 
GABAB1a from untreated neurons (control) was set to 100%. The data represent the mean ± SEM of 
27-34 neurons per experimental condition derived from three independent experiments. *** p< 
0.0001, two-tailed unpaired t-test. 
B, Total expression levels of GABAB1a (K->R) mutants are unaffected upon blocking lysosomal 
targeting by inactivation of Rab7. Neurons were transfected with HA-tagged wild type GABAB1a or 
GABAB1a(K->R) mutants together with GABAB2 and with either wild type Rab7 or with a non-
funtional mutant of Rab7 (Rab7(DN)) and analyzed for total expression levels of transfected GABAB1 
using HA antibodies. Left, representative images depicting total expression of transfected GABAB1a 
(scale bar: 7 μm). Right, quantification of fluorescence intensities. The fluorescence intensities of 
GABAB1a coexpressed with wild type Rab7 were set to 100%. The data represent the mean ± SEM of 
27-34 neurons derived from three independent experiments. *** p< 0.0001, two-tailed unpaired t-test. 
 
CaMKII controls sorting of GABAB receptor to lysosomes 
It was recently shown that CaMKII binds to GABAB receptors and phosphorylates GABAB1 
at  serine 867 (Guetg et al 2010). CaMKII-mediated phosphorylation of GABAB1 serine 867 
plays a key role in glutamate receptor-induced down-regulation of GABAB receptors, a 
condition that mimics ischemia (Guetg et al 2010). We therefore analyzed the involvement of 
CaMKII in the regulation of GABAB receptor cell surface expression under basal conditions 
using the CaMKII inhibitor KN93. Inhibition of CaMKII by KN93 increased the level of 
GABAB receptors at the cell surface (148 ± 10% of control; Fig. 6A), suggesting that basal 
CaMKII activity restricts cell surface expression of the receptors.  
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 To get an insight into the mechanism that is affected by CaMKII inhibition, we tested the 
co-localization of GABAB receptors with Rab7 (marker for late endosomes and lysosomes) 
and Rab11 (marker for recycling endosomes) (Ng et al 2012). Inhibition of CaMKII activity 
in neurons with KN93 decreased the number of GABAB receptor clusters co-localizing with 
Rab7 (80 ± 3% of control; Fig. 6B) and increased the number of GABAB receptor clusters co-
localizing with Rab11 (139 ± 9%, of control; Fig. 6C). Thus, inhibition of CaMKII appears to 
prevent recruitment of GABAB receptors to the lysosomal degradation pathway and enhances 
recycling of the receptors to the plasma membrane. This observation suggests that basal 
CaMKII activity is involved in targeting of GABAB receptors to lysosomes for degradation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. CaMKII regulates lysosomal degradation of GABAB receptors. 
A, Inhibition of CaMKII activity increased cell surface expression of GABAB receptors. Neurons were 
incubated for the indicated times with the CaMKII inhibitor KN93 (10 μM) followed by determination 
of cell surface GABAB receptors expression using GABAB1 antibodies. The immunofluorescence 
signals of untreated control neurons were set to 100%. Left, representative images (scale bar: 5 μm). 
Right, quantification of fluorescence intensities. The data represent the mean ± SEM of 39-43 neurons 
from three independent experiments. *** p< 0.0001; one way ANOVA, Dunnett’s Multiple 
Comparison test. 
B, C, Blocking CaMKII activity decreased the colocalization of GABAB receptors with the Rab7 
(marker for the lysosomal pathway) and increased the colocalization with Rab11 (marker for recycling 
endosomes). Neurons were treated with KN93 and immunostained for GABAB2 (red) and Rab7 or 
Rab11 (green). The yellow clusters in the merged image indicate the co-localization of GABAB2 with 
Rab7 or Rab11, respectively (left, representative images; scale bars: 5 μm). Right, quantification of 
colocalization. The data represent the mean ± SEM of 30-60 neurons from three independent 
experiments; *** p< 0.0005, two-tailed unpaired t-test. 
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CaMKII promotes K63-linked ubiquitination of GABAB receptors 
The results so far support the hypothesis that CaMKII regulates lysosomal degradation of 
GABAB receptors most likely by promoting K63-linked ubiquitination of GABAB receptors. 
To test this hypothesis, we first tested whether blocking CaMKII with KN93 affects K63-
linked ubiquitination of GABAB receptors. Indeed, GABAB receptors in KN63-treated 
neurons were considerably less K63-linked ubiquitinated as compared to receptors in 
untreated neurons (69 ± 8% of control, Fig. 7A). This finding shows that CaMKII regulates 
K63-linked ubiquitination of GABAB receptors.  
 Next; we tested whether blocking CaMKII affects cell surface expression of the three 
GABAB1a(K->R) mutants, which are partially resistant to K63-linked ubiquitination. In 
contrast wild type GABAB1, which displayed increased cell surface expression upon treatment 
with KN63 (GABAB1: 164 ± 20%, GABAB2: 155 ± 17% of control; Fig. 7B), the expression 
level of any of the three GABAB1a(K->R) mutants remained unaffected by inhibition of 
CaMKII (GABAB1a(K697/698R): 86 ± 5%, GABAB1a (K892R): 91 ± 6%, GABAB1a (K960R): 
99 ± 9% of control, GABAB2 co-expressed with GABAB1a (K697/698R), 85 ± 6%, GABAB2 
co-expressed with GABAB1a(K892R): 92 ± 7%, GABAB2 co-expressed with 
GABAB1a(K960R): 100 ±7% of control; Fig. 7B). In conclusion, these findings suggest that 
CaMKII promotes K63-linked ubiquitination of GABAB1 at K697/698, K892 as well as K960, 
which targets GABAB receptors to lysosomes for degradation. 
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Figure 7. CaMKII regulates Lys63-linked polyubiquitination of GABAB receptors. 
A, Inhibition of CaMKII activity reduced K63-linked ubiquitination of GABAB receptors. Neurons 
were incubated for 7.5 minutes in the absence (control) or presence of KN93 and analyzed for K63-
linked ubiquitination of GABAB receptor by in situ PLA using antibodies directed against GABAB1 
and K63-linked ubiquitin (white dots in representative images, left panel, scale bar: 5 μm). Right, 
quantification of in situ PLA signals. The data represent the mean ± SEM of 33 neurons from two 
independent experiments. **, p< 0.0013, two-tailed unpaired t-test. 
B, Blocking CaMKII did not affect the expression levels of GABAB1a(K->R) mutants. Neurons were 
transfected with HA-tagged wild type GABAB1a or HA-tagged GABAB1a (K->R) mutants along with 
GABAB2 and tested for cell surface expression of GABAB1 and GABAB2 after treating the neurons 
with 10 μM KN93 for 7.5 minutes. Left, representative images of untreated neurons (control, left 
panels) and of neurons treated with KN93 (right panels, scale bar: 5 μm). The corresponding graphs 
show the quantification of fluorescence signals. The fluorescence intensity of GABAB1 or GABAB2 
from untreated neurons (control) was set to 100%. The data represent the mean ± SEM of 50-60 
neurons per experimental condition derived from three independent experiments. ** p< 0.005, two-
tailed unpaired t-test. 
 
Sustained activation of glutamate receptors increases K63-linked ubiquitination of 
GABAB receptors 
Sustained activation of glutamate receptors (AMPA as well as NMDA receptors) leads to the 
down-regulation of GABAB receptors via lysosomal degradation (Guetg et al 2010, Maier et 
al 2010, Terunuma et al 2010). To investigate whether K63-linked ubiquitination of GABAB 
receptors serves as a lysosomal sorting signal in this process, we exposed cortical neurons for 
30 min to glutamate and tested for K63-linked ubiquitination using in situ PLA. Sustained 
activation of glutamate receptors dramatically increased K63-linked ubiquitination of GABAB 
receptors (524 ± 77% of control, Fig. 8A), which was completely prevented by blocking 
CaMKII with KN93 (123 ± 8% of control, Fig. 8A). 
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 Next we tested whether preventing K63-linked ubiquitination inhibits the down-regulation 
of GABAB receptors after treating neurons with glutamate. For this, cortical neurons were 
transfected either with wild-type ubiquitin (Ub), a mutant of ubiquitin in which all lysines 
were mutated to arginines thereby preventing chain elongation and thus any kind 
polyubiquitination (Ub(KO)) or with a mutant in which all lysines were mutated to arginines 
except for K63 (Ub(K63), able to form only K63-linked ubiquitination) and stained for cell 
surface GABAB receptors after sustained glutamate application. Glutamate induced down-
regulation of GABAB receptors from the plasma membrane in neurons expressing wild type 
ubiquitin (Ub(WT), 53 ± 5% of control, Fig. 8B), or the mutant that only permits K63-linked 
ubiquitination (Ub(K63), 61 ± 6% of control, Fig. 8B) but not in neurons expressing the 
mutant unable to build polyubiquitin chains (Ub(KO), 95 ± 11% of control, Fig. 8B). 
 To further confirm that ubiquitination of GABAB1 is required for glutamate-induced down-
regulation of GABAB receptors, we tested whether the expression of the GABAB1a(K->R) 
mutants is affected by glutamate. However, in contrast to the cell surface expression of wild 
type GABAB1 (56 ± 8% of control, Fig. 9), the levels of all three GABAB1a(K->R) mutants 
remained unaffected by glutamate (GABAB1a(K697/698R): 90 ± 12%, GABAB1a(K892R): 
115 ± 11%, GABAB1a (K960R): 108 ± 5% of control, Fig. 9).  
 These findings suggest that sustained activation of glutamate receptors induces CaMKII-
mediated K63-linked ubiquitination of GABAB receptors, promoting their lysosomal 
degradation. 
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Figure 8. Glutamate-induced down-regulation of GABAB receptors is mediated by Lys63-linked 
polyubiquitination. 
A, Sustained activation of glutamate receptors enhanced K63-linked ubiquitination of GABAB 
receptors. Neurons were incubated for 60 min in the absence (control) or presence of 50 μM glutamate 
with or without 10 μM KN93 and analyzed for K63-linked ubiquitination by in situ PLA using 
antibodies directed against GABAB1 and K63-linked ubiquitin (white dots in representative images, 
scale bar: 5 μm). The graph depicts quantification of the in situ PLA signals. The data represent the 
mean ± SEM of 47-52 neurons derived from three independent experiments. *** p< 0.0001; one way 
ANOVA, Dunnett’s Multiple Comparison test.  
B, Preventing K63-linked ubiquitination rendered GABAB receptors resistant to glutamate-induced 
down-regulation. Neurons were transfected with wild-type ubiquitin (Ub(WT)), and mutants of 
ubiquitin that either permits only K63 ubiquitination (Ub(K63)) or prevents any kind of ubiquitin 
chain generation (Ub(KO)). Neurons were incubated for 90 min in the absence (control) or presence of 
50 μM glutamate followed by determination of cell surface GABAB receptors using GABAB1 
antibodies. Left, representative images, scale bar: 5 μm. Right, quantification of fluorescence 
intensities. The data represent the mean ± SEM of 30-36 neurons from three independent experiments. 
*** p< 0.0001; two-tailed unpaired t-test. 
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Figure 9. GABAB1a(K->R) mutants are resistant to glutamate-induced down-regulation. 
Neurons transfected with HA-tagged wildtype GABAB1a or HA-tagged GABAB1a(K->R) mutants 
along with GABAB2 were incubated in the presence (Glutamate) or absence (Control) of 50 μM 
glutamate for 90 minutes followed by cell surface staining for transfected GABAB1 using HA 
antibodies. Left, representative images, scale bar: 5 μm. Right, quantification of fluorescence 
intensities. The fluorescence intensity of neurons not treated with glutamate was set to 100%. The data 
represent the mean ± SEM of 20-25 neurons per experimental condition derived from two independent 
experiments. *** p< 0.0005, two-tailed unpaired t-test. 
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Discussion  
The signaling strength of G protein coupled receptors largely depends on the number of 
receptors present in the plasma membrane. The mechanisms determining cell surface 
expression of the receptors include exocytosis, endocytosis, recycling and degradation. 
GABAB receptors assemble into heterodimeric GABAB1,2 complexes in the ER, which is a 
prerequisite for their ER exit and forward trafficking to the plasma membrane. After reaching 
the cell surface, GABAB receptors are constitutively internalized and either recycled to the 
plasma membrane or degraded in lysosomes (for a review see (Benke 2010)). Both, forward 
trafficking of GABAB receptors to the cell surface as well as their residence time at the cell 
surface are tightly regulated by controlled degradation of the receptors. The amount of 
GABAB receptors available for forward trafficking to the plasma membrane in the ER is 
adjusted by proteasomal degradation of the receptors via the ERAD machinery depending on 
the activity level of the neuron (Zemoura & Benke 2014, Zemoura et al 2013). On the other 
hand, the amount of receptors degraded in lysosomes after internalization from the cell 
surface depends on mechanisms sorting the endocytosed  receptors to either lysosomes or 
recycling endosomes. Interfering with recycling rapidly depletes the receptors from the cell 
surface by redirecting them to the lysosomal degradation pathway (Grampp et al 2008). Rapid 
down-regulation of cell surface GABAB receptors by rerouting the receptors to lysosomes 
appears to be associated with pathological conditions as it is induced by sustained activation 
of glutamate receptors, which is a characteristic of brain ischemia (Guetg et al 2010, 
Kantamneni et al 2014, Maier et al 2010, Terunuma et al 2010). The factors triggering 
lysosomal degradation of GABAB receptors were however unknown. The results of the 
present study provided evidence that CaMKII-dependent K63-linked ubiquitination of 
GABAB1 sorts GABAB receptors to lysosomes for degradation under physiological and 
pathological conditions. 
We found that pharmacological inhibition of lysosomal activity increased not only total 
GABAB receptor levels, which was expected due to the intracellular accumulation of the 
receptors (Grampp et al 2007), but also considerably the enhanced cell surface expression of 
the receptors. This finding implies that regulating lysosomal degradation of GABAB receptors 
directly affects their cell surface expression, which in turn determines the strength of GABAB 
receptors signaling (Zemoura et al 2013). There is evidence that K63-linked ubiquitination is 
required for lysosomal degradation of GABAB receptors. First, blocking global K63-linked 
ubiquitination by overexpressing an ubiquitin mutant (K63R) that is unable to form K63-
linked chains significantly increased cell surface expression of GABAB receptors. Second, 
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blocking lysosomal activity considerably increased the level of K63-linked ubiquitination of 
GABAB receptors while leaving the level of K48-linked ubiquitination, which tags the 
receptors for proteasomal degradation (Zemoura et al 2013), unaffected. Third, mutational 
inactivation of potential ubiquitination sites in GABAB1 (K697/698, K892 and K960) strongly 
decreased K63-linked ubiquitination of GABAB receptors containing the respective GABAB1 
mutant and prevented their lysosomal degradation as indicated by their dramatically increased 
expression level and insensitivity to the effect of blocking lysosomal degradation (either by 
inhibiting lysosomal proteases by leupeptin or by overexpression of a functionally inactive 
mutant of Rab 7, which inhibits transport of cargo from late endosomes to the lysosome and 
blocks lysosome biogenesis). Any of the three GABAB1 mutants (K697/698R, K892R and 
K960R) appeared to completely prevent lysosomal degradation of the receptors, suggesting 
that ubiquitination of K697/698, K892 and K960 in GABAB1 is mandatory for lysosomal 
degradation of GABAB receptors. However, it is currently unclear at which stage of 
intracellular sorting these sites needs to be ubiquitinated. They may be ubiquitinated 
simultaneously at a certain sorting step or, alternatively, they may be sequentially 
ubiquitinated at distinct sorting checkpoints.  
Lysosomal degradation of G protein coupled receptors is predominantly mediated via the 
ESCRT machinery (Dores & Trejo 2014), which guides mono- and K63-linked ubiquitinated 
membrane proteins to lysosomes (Lauwers et al 2009). Therefore, our observation that K63-
linked ubiquitination tags GABAB receptors for lysosomal degradation indicates that the 
ESCRT machinery also sorts GABAB receptors to lysosomes. This view is supported by the 
finding that the ESCRT I complex component TGS101 (Hurley & Emr 2006) is required for 
lysosomal degradation of GABAB receptors (Kantamneni et al 2008). 
Phosphorylation often regulates ubiquitination of proteins thereby promoting their 
degradation (Lin et al 2002, Schroeder et al 2012, Su et al 2013). Here we found that blocking 
CaMKII activity decreased K63-linked ubiquitination of GABAB receptors and increased 
their cell surface expression. Consistent with these findings, cell surface expression of all 
three GABAB1a(K->R) mutants with inactivated K63-linked ubiquitination sites remained 
unaffected by CaMKII inhibition. These findings indicate that basal CaMKII activity 
determines the level of K63-linked ubiquitination of GABAB receptors and thus the extent of 
their lysosomal degradation. Our colocalization experiments suggests that blocking CaMKII 
impairs lysosomal sorting of the receptors (reduced colocalization with Rab7) thereby 
fostering receptor recycling (increased colocalization with Rab11). This redirection of 
GABAB receptors to the recycling pathway explains the increased cell surface expression of 
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receptors after interfering with lysosomal degradation. It is currently unclear whether direct 
phosphorylation of GABAB receptors is required or the phosphorylation of proteins involved 
in sorting of the receptors. However, the observation that lysosomal degradation triggered by 
sustained activation of glutamate receptors depends on phosphorylation of GABAB1 by 
CaMKII (Guetg et al 2010) favors a direct phosphorylation of GABAB1 by CaMKII as a 
prerequisite for its K63-linked ubiquitination.  
Sustained activation of glutamate receptors, a situation occurring in brain ischemia, rapidly 
down-regulates GABAB receptors by increasing the rate of their lysosomal degradation at the 
expense of recycling (Guetg et al 2010, Kantamneni et al 2014, Maier et al 2010, Terunuma et 
al 2010). By overexpressing mutants of ubiquitin and the GABAB1(K->R) mutants in neurons, 
we now provide evidence that glutamate-induced down-regulation of GABAB receptors 
depends on CaMKII-mediated K63-linked ubiquitination of GABAB1. It was previously 
shown that glutamate-induced down-regulation of GABAB receptors critically depends on 
phosphorylation of GABAB1 at serine 867 by CaMKII (Guetg et al 2010). This suggests that 
the massive Ca
2+
 influx induced by prolonged neuronal excitation over-activates CaMKII, 
resulting in excessive phosphorylation and consequently K63-linked ubiquitination of 
GABAB1. In line with this view we observed a massive increase in K63-linked ubiquitination 
of GABAB receptors after sustained stimulation of glutamate receptors, which was completely 
abolished by blocking CaMKII. 
In conclusion, our data suggest that CaMKII regulates K63-linked ubiquitination of GABAB1 
at four distinct sites, which sorts GABAB receptors to lysosomes for degradation. This 
mechanism is expected to fine-tune cell surface expression of GABAB receptors under 
physiological conditions and to considerably affect receptor expression in diseases associated 
with disturbed Ca
2+
 homeostasis. 
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Starting situation and research questions 
GABAB receptors are important mediators in the modulation of neuronal function as they are 
responsible for slow and prolonged inhibitory transmission. Their signaling strength largely 
depends on the number of receptors present in the plasma membrane, which in turn is 
determined by their rate of exocytosis, endocytosis, recycling and degradation. In this thesis, 
we aimed at understanding if and how degradation pathways contribute to the regulation of 
cell surface expression of GABAB receptors. At the time of starting this research project 
several studies investigated how GABAB receptors reach the cell surface and a major 
mechanism for their endocytosis had been disclosed: the two subunits GABAB1 and GABAB2 
exit the ER after their heterodimerisation, reach the cell surface and are then constitutively 
endocytosed via the clathrin- and dynamin-dependent pathway (Grampp et al 2008a, Grampp 
et al 2007b, Hannan et al 2011b, Margeta-Mitrovic et al 2000, Ramirez et al 2009, Vargas et 
al 2008). Once endocytosed, the majority of receptors is recycled to the plasma membrane, 
while a minority is degraded (Grampp et al 2008a, Grampp et al 2007b, Vargas et al 2008). In 
contrast, little was known about the routes and the regulation of GABAB receptor degradation. 
There was solid evidence for their degradation in lysosomes as GABAB receptors had been 
shown to colocalize with lysosomal marker proteins (Grampp et al 2008a, Hannan et al 
2011a) and inhibition of lysosomal proteases led to their intracellular accumulation (Grampp 
et al., 2008; Maier et al., 2010). There was also indirect indication for ubiquitination being 
involved in lysosomal degradation of the receptors. Blocking global ubiquitination by 
inhibiting the ubiquitin-activating enzyme (E1) decreased lysosome-dependent glutamate-
induced degradation of GABAB receptors (Maier et al., 2010). In addition, it had been shown 
that a subcomplex of the endosomal complex required for sorting (ESCRT), known to target 
ubiquitinated membrane proteins to lysosomes (Katzmann et al 2001), contributes to the 
degradation of GABAB receptors (Kantamneni et al., 2008). There were also hints that 
GABAB receptors might be degraded by proteasomes as a second route. Inhibition of 
proteasomes increased the expression level of GABAB receptors ectopically expressed in 
HEK293 cells (Kantamneni et al., 2008). Taken together, this background raised a number of 
basic questions that we aimed to address in this research project: 
1. Are GABAB receptors degraded by proteasomes? 
2. Is ubiquitination involved in proteasomal as well as lysosomal of GABAB receptors? 
3. Where are relevant ubquitination sites located in GABAB receptors? 
4. Does degradation regulate cell surface expression of GABAB receptors? 
5. Is degradation of GABAB receptors regulated by neuronal activity? 
  
86 
 
In this thesis, we discovered that ubiquitin-mediated proteasomal as well as lysosomal 
degradation control cell surface expression of GABAB receptors depending on the activity 
level of the neurons.  
 
Neuronal activity controls cell surface expression of GABAB receptors via 
ERAD-mediated proteasomal degradation 
In this project we delineated a new mechanisms involved in the degradation of GABAB 
receptors. We found that GABAB receptors are K48-linked ubiquitinated at lysine residues 
767/771 in the C-terminal domain of GABAB2, which tags the receptors for proteasomal 
degradation (Zemoura et al 2013b). Proteasomal degradation involved the interaction of the 
C-terminus of GABAB2 with the proteasomal AAA-ATPase Rpt6 (Zemoura & Benke 2014). 
We revealed that proteasomal degradation of GABAB receptors takes place at the ER, 
involves the ERAD machinery (Zemoura et al 2013b) and is regulated by neuronal activity 
(Zemoura & Benke 2014). Most importantly, we found that increasing or decreasing 
proteasomal degradation of GABAB receptors affects cell surface expression of the receptors. 
Our findings are consistent with a model in which neuronal activity controls the number of 
GABAB receptors present in the ER by proteasomal degradation via the ERAD pathway. This 
determines the number of receptors available for forward trafficking to the cell surface (Fig. 
8). 
A key role in the proteasomal degradation of GABAB receptors plays the interaction of the C-
terminus of GABAB2 with Rpt6, which is one of the six AAA-ATPases present in the 19S 
regulatory particle of the proteasome (Rubin et al 1996). The 19S regulatory particle of the 
proteasome is thought to recognize, unfold, and translocate the K48-linked polyubiquitinated 
protein substrates into the 20S, protein-degrading, core particle (Voges et al 1999). Rpt6 has 
been shown to interact with different proteins and is thought to control the recognition and 
thus degradation of proteins by the proteasome (Ferrell et al 2000). The transcription factor 
Sp1 as well as the estrogen receptors ERa and ERb are examples for proteins that undergo 
proteasomal degradation via interaction with Rpt6 (Han & Kudlow 1997, Masuyama & 
Hiramatsu 2004, Nawaz et al 1999). Our finding that blocking proteasomal activity increases 
the colocalization of GABAB receptors with Rpt6 and the number of GABAB receptor clusters 
in the dendrites of neurons as well as the observation that overexpression of a dominant-
negative mutant of Rpt6 in neurons upregulates cell surface GABAB receptors demonstrates 
that Rpt6 mediates proteasomal degradation of GABAB receptors. 
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It is well established that misfolded and misassembled membrane proteins are rapidly 
removed from the ER membrane by the ERAD machinery and degraded in proteasomes 
located in the cytosol (Raiborg and Stenmark, 2009). Because GABAB receptors are 
transmembrane proteins that need to be removed from the membrane for proteasomal 
degradation, ERAD was the most likely pathway involved. Indeed, inhibition of proteasomal 
activity resulted in the accumulation of GABAB receptors in the ER and specific inhibition of 
the ERAD pathway by pharmacological tools or using a dominant-negative mutant of the 
AAA-ATPase p97, a component of the ERAD machinery, increased both total and cell 
surface GABAB receptor levels. These findings demonstrate that the ERAD pathway not only 
eliminates damaged membrane proteins but also regulates the number of receptors available 
for ER exit and transport to the cell surface. This view is supported by recent findings 
suggesting that ERAD is involved in the regulation of the abundance of synaptic GABAA 
receptors (Saliba et al., 2007).  
Most importantly, we found that chronic pharmacological manipulation of neuronal activity 
alters cell surface expression of GABAB receptors via changes in the level of their ERAD-
dependent proteasomal degradation (Zemoura & Benke 2014). Enhancement of neuronal 
activity reduced GABAB receptor cell surface expression whereas blocking neuronal activity 
increased their expression. Our observation that chronic changes in neuronal activity affect 
the activity of proteasomes is confirmed by published data (Djakovic et al., 2009; Jakawich et 
al., 2010; Djakovic et al., 2012) and provides - in part - a mechanistic link to the modulation 
of cell surface GABAB receptors. It has been shown that enhanced neuronal activity increases 
proteasome activity by a mechanism involving Ca
2+
 influx through NMDA receptors and L-
type voltage-gated Ca
2+
 channels (Djakovic et al., 2009). Increased proteasomal activity 
down-regulates GABAB receptors in the ER and consequently limits their cell surface 
delivery. However, further experiments are required to address the question what mechanism 
controls the extent of K48-linked ubiquitination of GABAB receptors. This most likely 
involves neuronal activity-dependent phosphorylation events, which may regulate the activity 
of a specific E3 ubiquitin ligases and deubiqutinating enzymes (Huntwork-Rodriguez et al 
2013) or primes the receptors for ubiquitination (Schwarz et al 2010). 
What are the physiological implications of this regulatory mechanism? It has been shown that 
chronic suppression or elevation of activity in cultured neuronal networks exerts opposing 
compensatory effects on the excitatory glutamatergic and inhibitory GABAergic system. 
Blocking neuronal activity increases the amplitude of AMPA miniature excitatory 
postsynaptic currents (mEPSCs), correlating with enhanced levels of cell surface AMPA 
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receptors, whereas it decreases the amplitude of GABA miniature inhibitory postsynaptic 
currents (mIPSCs), corresponding to diminished GABAA receptor levels in the plasma 
membrane (Turrigiano 2011). This homeostatic response increases excitability of neurons and 
is one mechanism that contributes to stabilizing the firing rate of neurons within a range 
required for proper network function. The increased level of cell surface GABAB receptors 
after sustained suppression of neuronal activity may be required for tightly controlling the 
upregulated excitability of the neuron. In this sense, increased levels of GABAB receptors 
likely represent an emergency break to prevent overshooting excitation under conditions of 
enhanced neuronal activity. 
 
 
 
Figure 8: Proteasomal degradation pathway of GABAB receptors. GABAB receptors are 
synthetized at the ER and trafficked to the cell surface were they are constitutively internalized via the 
clathrin and dynamin-dependent pathway. The majority of endocytosed  receptors are recycled to the 
plasma membrane, whereas a minority is degraded by lysosomes. The balance of all these events 
determines the amount of receptors on the cell surface and thus the maximum possible magnitude of 
signaling. Newly synthetized GABAB receptors in the ER are degraded by the ERAD machinery 
depending on the activity state of the neuron. This regulates the number of GABAB receptors in the 
ER available for forward trafficking to the plasma membrane and thus affects the level of cell surface 
receptors. Chronic depression of neuronal activity inhibits K48-linked polyubiquitination of GABAB2 
and their ERAD-mediated proteasomal degradation. Degradation of GABAB receptors by proteasomes 
requires K48-linked ubiquitination of GABAB2 at lysines 761/771 and the interaction of its C-terminus 
with the proteasomal AAA-ATPase Rpt6.   
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CaMKII-dependent K63-linked ubiquitination and lysosomal degradation 
of GABAB receptors 
In the second part of this thesis, we explored the role of lysosomal degradation in regulating 
the surface availability of GABAB receptors in neurons. We found that blocking lysosomal 
degradation indeed increased the expression level of cell surface GABAB receptors, which 
was dependent on K63-linked ubiquitination of GABAB1 at four distinct lysine residues. We 
showed that blocking CaMKII activity decreased K63-linked ubiquitination of GABAB1 and 
consequently inhibited lysosomal degradation of GABAB receptors. These results are 
consistent with a model in which CaMKII-mediated phosphorylation events (most likely 
direct phosphorylation of GABAB1 at serine 867 (Guetg et al. 2010)) induces K63-linked 
ubiquitination of GABAB1, which sorts the internalized receptors to lysosomes for 
degradation instead to the recycling pathway (Fig. 9). Our data imply that basal CaMKII 
activity under normal neuronal activity is sufficient to sort a minor fraction of GABAB 
receptors to lysosomes. Therefore, we hypothesize that CaMKII is part of a molecular switch 
that regulates the level of lysosomal degradation and recycling of GABAB receptors according 
to the activity state of the neuron. In line with this view, we found that sustained activation of 
glutamate receptors, which leads to a huge increase of intracellular Ca
2+
 levels and 
consequently enhanced CaMKII activity, induces massive CaMKII-mediated K63-linked 
ubiquitination of GABAB receptors and their down-regulation via lysosomal degradation (Fig. 
9).  
There are hints that this mechanism may regulate GABAB receptor expression in vivo. 
CaMKII has been implicated in both long term synaptic potentiation (LTP) as well as in long 
term synaptic depression (LTD), depending on the Ca
2+
 concentration, its isoform assembly 
(ratio of  and  isoforms) and autophosphorylation status (Coultrap & Bayer 2014, Pi et al 
2010, van Woerden et al 2009). There is evidence that also GABAB receptors regulate LTD. 
Activation GABAB receptors in the induction phase has been shown to increase the magnitude 
of LTD by enhancing mGluR1-mediated Ca
2+
 release from intracellular stores (Kamikubo et 
al 2007). Interestingly, rats sleep deprived for 12 hours show enhanced LTD in the CA1 
region of the hippocampus, which is associated with the upregulation of GABAB receptors 
(Tadavarty et al 2011). Considering that sleep deprivation decreases the expression level of 
CaMKII (Lopez et al 2008, Zagaar et al 2013, Zhang et al 2013), it may well be that the 
upregulation of GABAB receptors is due to reduced lysosomal degradation of GABAB 
receptors by diminished CaMKII-mediated K63-linked ubiquitination of GABAB1.  
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Cerebral ischemia is another condition which is most likely associated with CaMKII-mediated 
regulation of GABAB receptor degradation. Ischemic stroke leads to a massive release of 
glutamate, resulting in neuronal overexcitation and eventually neuronal death. Under normal 
conditions, glutamatergic neurotransmission is tightly controlled by GABAB receptors to 
prevent excessive excitation (Chalifoux & Carter 2011b). This mechanism is apparently not 
operative under ischemic conditions probably due to the down-regulation of GABAB 
receptors (Cimarosti et al 2009, Vollenweider et al 2006). 
Studies on cultured neurons mimicking the aspect of excessive glutamate receptor activation 
in cerebral ischemic revealed a rapid down-regulation of GABAB receptors, which was due to 
the re-routing of the receptors from the recycling pathway to lysosomal degradation and 
involved CaMKII-dependent phosphorylation of GABAB1 (Guetg et al, 2010; Kantamneni et 
al, 2014; Maier et al, 2010; Terunuma et al, 2010). This mechanism was later confirmed in the 
oxygen and glucose deprivation (OGD) in vitro model of cerebral ischemia (Kantamneni et al, 
2014). The results of this thesis uncovered the role of CaMKII in this mechanism. Glutamate-
induced enhanced CaMKII activity promotes K63-linked ubiquitination of GABAB1 and sorts 
the receptors, which normally recycle to the plasma membrane, to lysosomes for degradation. 
In the context of cerebral ischemia, the down-regulation of GABAB receptors is a detrimental 
event that is expected to foster excitotoxicity. 
We hypothesize that interfering with this mechanism may provide an opportunity to restore 
normal GABAB receptor expression in order to increase the inhibitory control under ischemic 
conditions. This is expected to combat overexcitation and to limit excitotoxic neuronal death. 
Because GABAB receptors directly interact with CaMKII (Guetg et al. 2010) small synthetic 
peptides mimicking the CaMKII binding site can be employed for disrupting the 
CaMKII/GABAB receptor interaction. This is expected to prevent the CaMKII-mediated K63-
linked ubiquitination of GABAB1 and the down-regulation of the receptors. It needs to be 
tested if restoring normal GABAB receptor expression under ischemic conditions indeed 
limits neuronal death. If this is the case, this strategy may serve as a starting point for a highly 
specific therapeutic intervention based on cell permeable interfering peptides. 
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Figure 9: Lysosomal degradation pathway of GABAB receptors. Under normal conditions 
(middle), GABAB receptors are constitutively endocytosed  from the plasma membrane and are sorted 
from early endosomes either to recycling endosomes or to lysosomes for degradation. CaMKII appears 
to play an important role in sorting the receptors to the lysosomal degradation pathway. CaMKII 
phosphorylation events (most likely the direct phosphorylation of GABAB1) lead to K63-linked 
ubiquitination of GABAB1, which serves as a signal for lysosomal targeting. The level of CaMKII 
activity determines the amount of receptors sorted to lysosomes and thereby regulates the amount of 
cell surface receptors. For instance, blocking CaMKII activity (left) inhibits K63-linked ubiquitination 
and lysosmal degradation of the receptors, which results in enhanced recycling and increased 
expression of cell surface receptors. On the contrary, overexcitation of neurons by sustained activation 
of glutamate receptors (right, GluR) enhances CaMKII activity, K63-linked ubiquitination of GABAB1 
and down-regulation of GABAB receptors. GB1: GABAB1, GB2: GABAB2, GluR: glutamate receptor, 
Ub, ubiquitin.  
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ABBREVIATIONS 
AAA-ATPase: ATPases associated with diverse cellular Activities 
AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
AP2-complex: Adaptor protein 2 complex 
CaMKII: Ca2+/calmodulin-dependent protein kinase II 
cAMP: Cyclic adenosine monophosphate 
CNQX: 6-cyano-7-nitroquinoxaline-2,3-dione 
CNS: Central nervous system 
COPI: coat protein complex I 
DMEM: Dulbecco's modified eagle medium 
E18: Embryonic of 18 days 
ER: Endoplasmic reticulum 
ERa: Estrogen receptor a 
ERAD: Endoplasmic-reticulum-associated protein degradation 
ERb: Estrogen receptor b 
ESCRT: Endosomal sorting complex required for transport 
GABA: Gamma-aminobutyric acid 
GABAA: Gamma-aminobutyric acid A receptor  
GABAB1a: Gamma-aminobutyric acid B receptor 1 type a 
GABAB1b: Gamma-aminobutyric acid B receptor 1 type b 
GABAB2: Gamma-aminobutyric acid B receptor 2 
GPCR: G protein-coupled receptor 
HEK 293: Human embryonic kidney 293 cells 
HRD1: ERAD-associated E3 ubiquitin-protein ligase 
KN-93: N-[2-[N-(4-Chlorocinnamyl)-N-methylaminomethyl]phenyl]-N-(2-hydroxyethyl)-4 
methoxybenzenesulfonamide 
mEPSC: miniature excitory postsynaptic current 
mEPSCs: miniature excitatory postsynaptic currents  
MG 132: N-[(Phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3 -methylbutyl]-
Lleucinamide 
mIPSCs: miniature inhibitory postsynaptic currents 
NMDA: N-methyl-D-aspartate 
PBS: Phosphate-buffered saline 
PLA: proximity ligation assay 
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PTX: Picrotoxin 
Rab:  Ras superfamily of monomeric G proteins  
Rpt6: One of the six AAA-ATPase of the proteasomal 19S regulatory complex 
Sp1: Stimulatory protein 1 
sPSC :spontaneous postsynaptic current 
TTX: Tétrodotoxine 
Ub: ubiquitin 
VCP (P97): Valosin-containing protein 
WT: wild type 
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